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The outcomes of Coronavirus disease-2019 (COVID-19) vary depending on the age,
health status and sex of an individual, ranging from asymptomatic to lethal. From an
immunologic viewpoint, the final severe lung damage observed in COVID-19 should be
caused by cytokine storm, driven mainly by interleukin-6 and other pro-inflammatory
cytokines. However, which immunopathogenic status precedes this “cytokine storm”
and why the male older population is more severely affected, are currently unanswered
questions. The aging of the immune system, i.e., immunosenescence, closely
associated with a low-grade inflammatory status called “inflammageing,” should play
a key role. The remodeling of both innate and adaptive immune response observed
with aging can partly explain the age gradient in severity and mortality of COVID-
19. This review discusses how aging impacts the immune response to the virus,
focusing on possible strategies to rejuvenate the immune system with stem cell-
based therapies. Indeed, due to immunomodulatory and anti-inflammatory properties,
multipotent mesenchymal stem cells (MSCs) are a worth-considering option against
COVID-19 adverse outcomes.
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INTRODUCTION
From December 2019 onwards, SARS coronavirus 2 (SARS-CoV-2) infection spread across the
globe so rapidly that, on March 11, 2020, the World Health Organization (WHO) declared
coronavirus disease-2019 (COVID-19) a global pandemic. While the pandemic is still in progress,
the global scientific and medical community is focusing its resources on developing both anti-
COVID-19 vaccines and therapeutic drugs, in order to gain control over the quick spread of this
novel coronavirus.
SARS-CoV-2 is a Betacoronavirus of the Coronaviridae family that, like the other respiratory
coronaviruses, is transmitted primarily via respiratory droplets, preferentially infecting lung
alveolar epithelial cells using the human angiotensin-converting enzyme II (ACE2) as an entry
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receptor and the transmembrane serine protease 2 (TMPRSS2),
which cleaves viral spike, for priming (Hoffmann et al., 2020;
Wan et al., 2020).
This virus may infect people regardless of age, sex, and
ethnicity but with different symptomatic presentation and
outcomes. Indeed, clinical manifestations can range from being
mild to severe respiratory disease, with a mean incubation period
of approximately 5 days before first symptoms onset (Lauer et al.,
2020; Li Q. et al., 2020; McAloon et al., 2020).
Fever, fatigue and dry cough are the most common symptoms
in patients with mild or moderate disease. Severe characteristic
symptoms include pneumonia, dyspnoea and subsequently acute
respiratory distress syndrome (ARDS) that requires intensive
care unit (ICU) admission with intubation and mechanical
ventilation and can be fatal. In some cases, infected patients can
present as either asymptomatic or paucisymptomatic, with little
or no clinical manifestations (Baj et al., 2020; Chen N. et al., 2020;
Gao Z. et al., 2021).
Although the majority of COVID-19 cases are mild
symptomatic with a moderate case-fatality rate (Fu L. et al.,
2020), older patients are at higher risk of getting severe COVID-
19 disease, including hospitalization, and death (Wu and
McGoogan, 2020). Last April, there were 140,322,903 confirmed
COVID-19 cases and 3,003,794 deaths reported worldwide
(World Health Organization, 2021), while in Italy, 3,870,131
total cases of COVID-19 and 116,927 deaths have been registered
(Ministero della Salute, 2021). As of March 31, 2021, almost 86%
of SARS-CoV-2 positive Italian patients that died were patients
over 70 years old, with a mean age of 81 years and a median
of 82 years (range 0–109), more than 30 years higher than that
registered in infected people (median age 47; 51.2% females,
48.8% males) (Epicentro. Istituto Superiore di Sanità, 2021).
Disease severity in older patients is due to not only the viral
infection but also to host-related factors that make the individual
particularly vulnerable to more severe outcomes of the infection.
An optimal model for identifying the host factors involved
in susceptibility and/or protection to SARS-CoV-2 infection is
represented by the centenarians, i.e., subjects who have reached
ten or more decades of life, escaping the common age-related
diseases. Their ability to repair damages and respond well
to stressors is due to a combination of “positive features,”
including intrinsic (genetic), extrinsic (environmental), and
stochastic factors. Chance and life circumstances, nutrition,
physical activity, and environmental exposures, pathogen burden
and biology, with sex, genetic and epigenetic factors are all factors
that may contribute to the longevity phenotype (Caruso, 2019).
As a result, centenarians exhibit an optimal performance of the
immune system, which contributes to their surprising tendency
to recover from COVID-19 and complications (Lio et al., 2021).
On the other hand, since the immune response to SARS-CoV-
2 involves both innate and acquired immunity, dysregulation of
the immune system has important consequences for the ability
of the immune system to mount an effective response against
the pathogen. Therefore, the remodeling of the immune response
observed with aging can partly explain the age gradient in severity
and mortality of COVID-19 (Cunha et al., 2020). In this context,
the favorable prognosis and less severe signs on admission when
hospitalized observed in young people may depend on an efficient
acquired immune response against the virus (Gómez-Belda et al.,
2021). On the other hand, the older immune system exhibits
both cellular and humoral responses that are not efficient enough
to limit infection and innate responses that are more prone to
uncontrolled activation (Cunha et al., 2020). Various age-related
quantitative and qualitative impairments have been reported
in both innate and acquired immune responses, and they are
commonly known as “immunosenescence.” Reduction in the
ability to respond to new antigens, attributed to insufficient
production of naïve immune cells, and increased memory
responses, due to the lifelong antigen-exposure during persistent
viral infections, have been associated with immunosenescence
(Brunner et al., 2011; Aiello et al., 2019). With advancing
age, there is gradual atrophy of the thymus, responsible for
the development and selection of immunocompetent T cells
(Kurd and Robey, 2016). This phenomenon, called thymic
involution, involves structural changes in tissue mass and
cellularity, as well as functional decline, ultimately resulting
in a significantly decreased thymic output of naïve T cells,
important for the response to novel pathogens that have not
yet been encountered, contributing to shrinkage of the T cell
diversity repertoire (Palmer, 2013). Since SARS-CoV-2 is a novel
coronavirus with seemingly no prior sensitization, the naïve T
cell decline caused by thymic involution might contribute to
the increased vulnerability to severe COVID-19 outcomes in
the older population, as well as reduced vaccination efficiency
(Genebat et al., 2021; Wang et al., 2021).
Another characteristic of the older immune system is
the presence of a chronic, low-grade inflammation, called
inflammageing (Franceschi and Campisi, 2014), associated with
increased production of pro-inflammatory cytokines, acute phase
proteins, and oxidative stress (Fulop et al., 2018; Aiello et al.,
2019). Inflammageing is considered one of the main risk factors
for many age-related degenerative diseases and is caused by
several factors, including life-long antigenic stimulation of the
innate immune system by chronic infections, senescent cells
and their senescence-associated secretory phenotype (SASP)
(De Martinis et al., 2005; Hearps et al., 2012; Franceschi and
Campisi, 2014). As a consequence, there is an increase in serum
inflammatory mediators with age, including interleukin (IL)-
6, tumor necrosis factor (TNF)-α, IL-1, and C-reactive protein
(CRP) (Franceschi and Campisi, 2014; Barbé-Tuana et al., 2020).
This inflammatory environment could exacerbate the immune
response to the SARS-CoV-2. It has previously been seen that a
dysregulated and excessive inflammatory response is responsible
for sub-optimal T cells, antibody responses and impaired virus
clearance which ultimately lead to worsening of SARS-CoV-
1 and MERS-CoV infections, discovered in November 2002
and June 2012 respectively, with approximately 80 and 50%
genetic similarity with SARS-CoV-2 respectively (To et al.,
2013; Channappanavar and Perlman, 2017; Rabaan et al., 2020).
Similarly, in SARS-CoV-2 infection, uncontrolled inflammation
leads to severe and irreversible multi-organ damage, especially on
the cardiac, hepatic and renal systems (Tian et al., 2020).
In the early phases of infection occurring in the respiratory
tract, SARS-CoV-2 infected cells produce damage-associated
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molecular patterns (DAMP), such as ATP and nucleic acids,
which are recognized by neighboring epithelial cells, endothelial
cells and alveolar macrophages. This triggers the production of
various pro-inflammatory cytokines and chemokines, allowing
the recruitment of innate and acquired immune cells to the site
of infection, including T cells (Tay et al., 2020; Ortega et al.,
2021). In a healthy immune system, this initial inflammation
recruits and activates virus-specific CD4+ and CD8+ T cells
that kill the infected cells before the virus spreads, indirectly
via induction of neutralizing antibody production o directly
by inducing apoptosis, respectively. In a dysfunctional immune
response, the accumulation of immune cells in the lungs can lead
to the overproduction of pro-inflammatory cytokines, causing
local cell and tissue damage with systemic implications (Tay et al.,
2020). Considering that some cytokines can be both helpful in
controlling the infection progression and harmful to the host, it is
not easy to define a border between a regulated and a dysregulated
response to a severe infection. Elevated levels of circulating
cytokines, known as “cytokine storm,” were reported in COVID-
19 patients, with variability in onset and duration in the early
stages of infection but with convergent and often overlapping
late-stage clinical manifestations (Fajgenbaum and June, 2020).
SARS-CoV-2 can infect also monocytes and macrophages
through ACE2, by receptor-mediated endocytosis, and
independently on ACE2, by pattern recognition receptors
(PPRs), mechanisms. That results in their activation and
secretion of large amounts of pro-inflammatory mediators,
which contribute to local tissue and systemic inflammation
(Jafarzadeh et al., 2020; Moore and June, 2020). Thus, in
a scenario where the SARS-CoV-2 infection itself causes
an excessive and uncontrolled systemic release of pro-
inflammatory cytokines, the inflammageing process can
aggravate this condition, amplifying inflammatory events and
favoring the insurgence of ARDS, multiple organ failure, and
finally death in severe COVID-19 older patients (Meftahi
et al., 2020). For these reasons, it could be suggested
that early identification of individuals at higher risk of
virus-induced cytokine storm could help to determine
the most effective treatment to prevent irreversible organ
damage contributing to the relatively high mortality in older
COVID-19 patients.
Also, it has been hypothesized that the accumulation of highly
differentiated T cells with senescence-like features, together
with inflammageing, may contribute to the destruction of
lung tissue observed in severe COVID-19 patients (Akbar and
Gilroy, 2020). Several studies have shown an expansion of
senescent T cells in old individuals, driven by ongoing sub-
clinical responses to chronic or persistent infections (Pawelec,
2018). These senescent T cells can express the natural killer
cell receptors (NKRs) and can infiltrate into various tissues
including the lung, acting as natural killer (NK) cells, thus
promoting cytotoxicity against cells that expressed NKR ligands
without prior antigen-specific priming (Pereira et al., 2020).
According to this hypothesis, inflammation induced by SARS-
CoV-2 infection in the lungs, hypothetically exacerbated by
inflammatory monocytes infiltrated, would induce the expression
of NKR ligands by epithelial cells of the host respiratory tract and
lungs, and these may be recognized and killed by NK-like T cells
(Akbar and Gilroy, 2020).
The severity of the disease, therefore, seems to depend
primarily on the age and immune dysfunction. Nevertheless,
these alone may still not be sufficient to explain the highest
number of CFR in over 70 years population in South Korea,
Spain, China, and Italy (Our World in data, 2021). Another
important risk factor associated with the complications of
COVID-19 is the presence of comorbidities, such as arterial
hypertension, diabetes, and obesity, and older people are more
likely to have these conditions (Guo L. et al., 2020; Li X. et al.,
2020; Peña et al., 2020; Fresán et al., 2021). Many reports have
confirmed the association between comorbidities and COVID-
19 severity (Gao Y. D. et al., 2021), although it should be kept
in mind that their high prevalence in the older population could
be a confounding factor. The role of genetics is under scrutiny
(Pojero et al., 2021).
In addition to all these risk factors, there is growing evidence
of sex differences in severity and mortality of COVID-19.
Specifically, when the fatality rate was stratified for gender, it was
seen that males accounted for the majority of COVID-19 deaths
with similar pieces of evidence in different countries (Alkhouli
et al., 2020; Heras et al., 2020; Jin et al., 2020; Pradhan and
Olsson, 2020; Sha et al., 2021). In Italy, the spread of COVID-
19 has hit females (51.2%) slightly more than males (48.8%).
However, data suggest that the mortality rate was higher for males
than it was for females. Among all age groups, female Italian
patients who died with complications associated with SARS-
CoV-2 infection represented 43.9% and were older than men
(median age: females 86 years, males 80 years). The mortality
rate for female patients was 2.6%, while for male patients was
3.5% (Epicentro. Istituto Superiore di Sanità, 2021). This gender
discrepancy of COVID-19–related morbidity and mortality can
be attributed to a combination of biological sex differences,
including differences in sex hormones involved in inflammatory
processes and in expression levels of ACE2 and TMPRSS2,
but literature data are not yet coherent (Gebhard et al., 2020;
Haitao et al., 2020).
The role of sex hormones in immune responses has already
been extensively investigated (Moulton, 2018; Márquez et al.,
2020b; Fathi et al., 2021). Females show higher levels of estrogen
and progesterone, with considerable fluctuations throughout the
life span, while testosterone is more expressed in males, and
these hormonal differences are assumed to play an important
role in the innate and acquired immune responses (Fathi et al.,
2021). For example, there is a large body of evidence for the
role of estrogen in B cell development and activation and in
various functions of T cells, in particular CD4+ T cells (T
helper or TH) including differentiation, activation, cytokine
production, homeostasis, and regulatory functions (Moulton,
2018). Estrogens have also been implicated in the homeostasis
and activation of plasmacytoid dendritic cells (pDCs), key cells
in antiviral immunity. Human female pDCs produce significantly
higher interferon (IFN)-α levels in response to viral nucleic acids
or Toll-like receptor (TLR) 7 agonists than pDCs derived from
males, resulting in stronger secondary activation of CD8+ T cells
(T cytotoxic or CTL) with impact on viral infection response
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(Berghöfer et al., 2006; Meier et al., 2009). The stronger responses
observed in females result in faster pathogen clearance and a
better response to vaccines, but could also be responsible for
greater susceptibility to autoimmune diseases, considering that
80% of systemic autoimmune disorders occurring in females
(Klein and Flanagan, 2016). In comparison to estrogens, several
studies reported that exposure to androgens induces suppression
of immune reactivity, affecting different immune cell subsets
(Gubbels Bupp and Jorgensen, 2018). Detailed analysis on the
sex differences in immune phenotype in SARS-CoV-2 infection
has detected that, although plasma levels of many inflammatory
cytokines and chemokines were generally elevated in patients,
IL-8, IL-18, and CCL5 levels were significantly higher in male
compared to female patients (Takahashi et al., 2020), suggesting a
high risk of the cytokine storm.
It has also been proposed that the high plasma levels of
ACE2 observed in males may partly explain their increased
susceptibility to SARS-CoV-2 infection (Sama et al., 2020),
although another study reported no differences in ACE2
expression in various human tissues between males and females
or between young and old people (Li M. Y. et al., 2020).
Similarly, an association between increased COVID-19 severity
in males and expression of TMPRSS2, which is involved in
cellular entry of the virus, has been theorized. TMPRSS2 gene
expression is modulated by the androgen receptor signaling and
increases following exposure to androgens (Lin et al., 1999).
The upregulated TMPRSS2 expression in response to androgens
could explain the sex-discrepancy in COVID-19 outcomes
(Mjaess et al., 2020).
Therefore, immunosenescence, inflammageing (i.e.,
immunopathology), comorbidities, as well as male gender, play
an important role in contributing to increased vulnerability to
severe SARS-CoV-2 infection outcomes in older adults. Thus, the
heterogeneity of patients makes it difficult to identify a consensus
COVID-19 immune signature. In addition, some variability in
the parameters used to classify the severity of COVID-19 could
contribute to making it more difficult to compare the findings.
However, understanding the immunological status prior to
encountering the novel virus and how this is affected during
infection provides interesting targets for better understanding
the pathogenesis and treatment of SARS-CoV-2 infection.
In this review, we provide a detailed assessment of how
aging impacts the immune response to the virus, providing
when possible a parallelism with COVID-19-induced immune
changes, focusing on possible strategies to rejuvenate the
immune system with stem cell-based therapies. Indeed, due
to immunomodulatory and anti-inflammatory properties,
multipotent mesenchymal stem cells (MSCs) are a worth-
considering option against COVID-19 adverse outcomes
(Moradinasab et al., 2021).
CYTOKINE STORM IN COVID-19
DISEASE
Several analyses of the cytokine profile from COVID-19 patients
have correlated the cytokine storm with lung tissue damage,
multi-organ failure, and disease severity. Cellular origins of this
large amount of cytokines is difficult to identify since SARS-
CoV-2 infection requires the engagement of several immune
cells, including the innate macrophages, dendritic cells, natural
killer cells, and T and B lymphocytes (Ragab et al., 2020).
It was reported significantly increased plasma levels of pro-
inflammatory cytokines, including IL-1β, IL-6, IL-7, IL-8, IL-9,
IL-10, interferon (IFN)-γ, and TNF-α in patients with COVID-
19 than in healthy adults, but similar levels of IL-5, IL12p70,
and IL-15. In addition, severe cases admitted to the ICU have
shown higher plasma concentrations of IL-2, IL-7, IL-10, TNF-
α, and other cytokines and chemokines than non-ICU patients
(Huang et al., 2020). Levels of IL-6, mediator of the acute
inflammatory response, and C-reactive protein (CRP), non-
specific marker of inflammation, in these patients continue to
increase over time and is significantly associated with ARDS
and death in COVID-19 patients (Herold et al., 2020; Ruan
et al., 2020; Wu et al., 2020; Zhou F. et al., 2020). Also
analysis in bronchoalveolar lavage (BAL) fluid, a source of
information of the microenvironment on bronchioles and lung
alveoli, have shown higher levels of inflammatory cytokines,
including IL-8, IL-6, and IL-1β, in severe cases compared to
patients with moderate COVID-19 infection (Liao et al., 2020).
When compared to survivor recovered patients, remarkably
higher serum levels of IL-2R, IL-6, IL-8, IL-10, and TNF-α at
admission were found in COVID-19 deceased patients, with a
rapid increase during hospitalization, reinforcing the idea that
dynamics of these cytokines and related receptors were highly
associated with disease outcome (Cui et al., 2020). Likewise,
it is reasonable to assume that the appropriate production of
anti-inflammatory cytokines can counterbalance the systemic
inflammation that occurs after infection. In male centenarians, it
has been observed overexpression of anti-inflammatory variants
in immune/inflammatory genes that could protect them from
damaging effects of the cytokine storm associated with COVID-
19 disease (Lio et al., 2021). Thus, cytokine storm prevention and
control may be a crucial strategy in the treatment of COVID-
19 patients. In line with that, it was proposed different anti-
inflammatory strategies, in order to avoid or at least alleviate the
cytokine storm. Among these, the use of IL-37 and IL-38 was
suggested as potential therapeutic cytokines capable of inhibiting
IL-1β and IL-6 (Conti et al., 2020).
INNATE IMMUNITY: NATURAL KILLER
(NK) CELLS
Natural killer cells are large granular lymphocytes, which
play an important role in the host first line of defense against
viral targets, via cell-mediated cytotoxicity mechanisms
(CD56lowCD16+ subset) and secretion of pro-inflammatory
cytokines (CD56hiCD16- subset). Among cytokines secreted
by NK cells there are IFN-γ, with both antiviral and immune
enhancing capabilities, TNF-α and granulocyte/macrophage
colony-stimulating factor (GM-CSF) that can modulate
the function of other innate and acquired immune cells
(Mirandola et al., 2004; Paul and Lal, 2017). Thus, in addition
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to directly lysing the infected cell, NK cells are able to activate
and mobilize other immune cells, including DCs, involved in
the early stages of infection. Evidence of the critical role of NK
cells in limiting viral infection prior to the induction of acquired
immune responses has been provided by clinical studies of
individuals who are deficient in NK cells and/or their functions,
leading to current infections by viral pathogens (Orange,
2013). Likewise, changes in NK cell count, phenotype, and
functions during aging may have a direct impact on COVID-19
disease progression.
Although less consistently than T cells (see below), NK cell
numbers are reduced in COVID-19 patients, particularly evident
in severe cases compared with mild disease patients and healthy
controls (Jiang et al., 2020; Zheng M. et al., 2020; Belaid et al.,
2021; Taghiloo et al., 2021), and their functional exhaustion
was correlated with disease progression (Zheng M. et al., 2020).
Single-cell analyses of bronchoalveolar samples of patients with
COVID-19 have shown the presence of NK cells in the immune
cell population analyzed, suggesting NK cell trafficking into the
site of infection (Chua et al., 2020; Liao et al., 2020). Cytotoxic
CD56low NK cells were depleted mainly in patients requiring
mechanical ventilation, whereas cytokine-secreting CD56hi NK
cells were significantly depleted in all COVID-19 patients (Wilk
et al., 2020; Table 1).
Conversely, an increase in peripheral NK cell frequency and
absolute cell count has been observed with advancing age, with
a decreasing fraction and cytokines production of CD56hi NK
cell subset and an expansion of CD56low NK cells (Solana et al.,
2014; Gounder et al., 2018). Whether this correlates with disease
severity in the older person is unclear.
Additionally, NK cell cytotoxic and secretory functions are
tightly regulated by a dynamic balance between activating
and inhibitory signals from an arsenal of membrane
receptors, including killer cell immunoglobulin-like receptors
(KIRs), randomly generated during NK cell differentiation
and maturation (Vidal et al., 2011). Specific KIR/ligand
interactions seem to be associated with COVID-19 disease
severity as demonstrated in a very recent paper (Bernal et al.,
2021) and by preliminary results from our ongoing study
(unpublished observations).
OTHER CELLS OF INNATE IMMUNITY:




In addition to NK cells, there are other important players of the
innate immune system that provide the host’s first line of defense
to the virus. Pattern recognition receptors (PRRs) expressed on
innate immune cells, such as DCs and macrophages, recognize
and bind surface viral epitopes, leading to anti-pathogen
responses. The activation of these cells by the virus leads secretion
of several inflammatory cytokines and chemokines, which
activate and recruit other immune cells generating a positive
feedback loop of inflammation (Pérez-Galarza et al., 2021). Aging
alters also these actors involved in innate immunity in terms
of both number/percentage and functionality, with different
quantitative and qualitative consequences for DCs, monocytes,
macrophages, neutrophils and myeloid derived suppressor cells
(MDSCs) (Agrawal et al., 2017; Ventura et al., 2017; Oh et al.,
2019; Feng et al., 2021). These changes in immune response may
TABLE 1 | Observed fluctuation in NK cells in adult COVID-19 patients.
NK cell subsets Observation Analyzed patients Compared group(s) References
CD16+CD56+ Reduction (%) Deceased Survivors Cui et al., 2020
Reduction (#) Deceased Survivors Cui et al., 2020; Belaid et al., 2021
Reduction (#) Pneumonia patients HD Wang F. et al., 2020
No change (#) Severeη Mild Wang F. et al., 2020
Reduction (#) Severeη Mildζ /moderateθ Belaid et al., 2021
Reduction (#) Cases HD Jiang et al., 2020
CD16+ No change (%) Cases HD Taghiloo et al., 2021
Reduction (#) Severeη Mildζ Taghiloo et al., 2021
CD56+ No change (%) Cases HD Taghiloo et al., 2021
Reduction (#) Severeη Mildζ Taghiloo et al., 2021
CD56low Reduction (%) Criticalι HD Wilk et al., 2020
CD56hi Reduction (%) Cases HD Wilk et al., 2020
BAL NK cells Reduction (%) Severeη /Criticalι Moderateθ Liao et al., 2020
Increase (%) Moderateθ HD Liao et al., 2020
NK cell subset, peripheral blood NK cell subset analyzed in the reported studies; BAL, bronchoalveolar lavage; (%), as frequency values; (#), as absolute number; Cases,
COVID-19 patients (irrespective of severity); HD, healthy donors.
ζPatients with clinical signs of pneumonia with one of the following: respiratory rate > 30 breaths/min, severe respiratory distress, or SpO2 < 90% on room air.
ηPatients experiencing the following: respiratory failure, respiratory rate > 30 bpm, oxygen saturation < 93% at rest, arterial partial pressure of oxygen (PaO2)/fraction of
inspired oxygen (FiO2) (PaO2/FiO2) ratio < 300 mmHg.
θFever, signs of airway disease, with or without a tomographic image indicating pneumonia.
ιAny of the following: requirement for mechanical ventilation, shock, or concomitant organ failure.
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have an important impact in first phases of viral replication. In
the following sections, we will discuss specific alterations in the
other innate immunity cells in COVID-19 patients recalling those
observed in the older immune system.
Although a clear difference in terms of severity and mortality
was demonstrated comparing female and male COVID-19
patients as anticipated, to the best of our knowledge no study
deeply explored sex related differences in SARS-CoV-2 infection
as regards innate immunity.
Dendritic Cells (DCs)
Dendritic cells are important immune cells, specialized to uptake,
process and present antigen to naïve T cells, thus linking innate
and acquired immunity. After pathogen internalization through
recognition by PRRs, including TLRs, DCs process and present
viral peptides to T cells via human leukocyte antigens (HLA)-T
cell receptor (TCR) interaction, leading to activation of T cells.
Peripheral DCs are historically classified into three subsets
based on their phenotype and functional characteristics: two
subsets of myeloid DCs (mDCs) and one subset of plasmacytoid
DCs (pDCs). The CD141+ mDC subset, named also myeloid
(conventional) DC1 (cDC1), and CD1c+ mDCs, or cDC2, is
both the primary source of IL-12, driving a TH1 response, but
these cells are also able to secrete IL-6 and TNF-α. CD123+
pDCs, instead, produce high amounts of type I IFNs, critical
for antiviral response (Collin et al., 2013; Mathan et al., 2013).
An additional subset of DCs, called slanDCs, was identified by
the use of M-DC8 monoclonal antibody, directed against the
6-sulfo LacNAc1 -slan- carbohydrate modification of P-selectin
glycoprotein ligand-1. These cells are highly proficient in
secreting inflammatory cytokines in both autoimmunity and
infections (Schäkel et al., 1998; Dutertre et al., 2012; Günther
et al., 2012; Hänsel et al., 2011, 2013; Tufa et al., 2014, 2016;
Micheletti et al., 2016; Iannetta et al., 2019).
As regards the involvement of DCs in determining SARS-
CoV-2 infection susceptibility and COVID-19 severity,
experimental data demonstrated that TLR7 plays a critical
role through viral single-stranded RNA recognition in the
TABLE 2 | Observed fluctuation in DCs and DC subsets in adult COVID-19 patients.
DC type Observation Analyzed patients Compared group(s) References
DCs Reduction (%) Hospitalized HD Zhou R. et al., 2020
Reduction (%) Convalescent HD Zhou R. et al., 2020
CD11c+ cDCs Reduction (%) Hospitalized Convalescent Zhou R. et al., 2020
Reduction (%)/ Severe/Critical+ HD Matic et al., 2020
Reduction (%)/ Severe/Critical+ Mild/Moderate& Matic et al., 2020
No change (%) Mild$ Convalescent Neeland et al., 2021
Increase (%) Mild/Moderate& HD Matic et al., 2020
CD123-CD11c+ myeloid DCs Reduction (%) Pneumonia HD Zingaropoli et al., 2021
Reduction (%) ARDS non-ARDS Zingaropoli et al., 2021
CD11c+ slanDCs Reduction (%) Pneumonia HD Zingaropoli et al., 2021
AXL+SIGLEC6+ pre-DCs Reduction (#) Cases HD Kvedaraite et al., 2021
AXL+CD1c+ pre-DC2 Reduction (#) Cases HD Kvedaraite et al., 2021
CLEC9A+ cDC1 Reduction (#) Cases HD Kvedaraite et al., 2021
CLEC9A- cDC2* Reduction (#) Cases HD Kvedaraite et al., 2021
CD163-CD14- DC3 Reduction (#) Cases HD Kvedaraite et al., 2021
CD163-CD14+ DC3 Reduction (#) Cases HD Kvedaraite et al., 2021
CD163+CD14+ DC3 Reduction (#) Cases HD Kvedaraite et al., 2021
CD5+DC2 Reduction (%) Severe§ Moderate@ Kvedaraite et al., 2021
CD163-CD14- DC3 Reduction (%) Severe§ Moderate@ Kvedaraite et al., 2021
AXL+CD1c+ pre-DC2 Increase (%) Severe§ HD Kvedaraite et al., 2021
CD123+CD11c- pDCs Reduction (#) Cases HD Kvedaraite et al., 2021
Reduction (%) ARDS non-ARDS Zingaropoli et al., 2021
Reduction (%) Pneumonia HD Zingaropoli et al., 2021
CD123+Lyn- pDCs Reduction (%)/ Severe/Critical+ HD Matic et al., 2020
Reduction (%)/ Severe/Critical+ Mild/Moderate& Matic et al., 2020
Reduction (%) Mild/Moderate& HD Matic et al., 2020
DC, dendritic cell; cDCs, conventional dendritic cells; pDCs, plasmacytoid dendritic cells; (%), as frequency values; (#), as absolute number; HD, healthy donors; ARDS,
acute respiratory distress syndrome; Cases, COVID-19 patients (irrespective of severity).
/No statistically significant data provided.
+Fever or suspected respiratory infection with compromised respiratory function and worsening of respiratory symptoms with the necessity for mechanical ventilation.
&Mild clinical symptoms of upper respiratory tract viral infection and signs of pneumonia without need for supplemental oxygen.
*Including CD5+ DC2 and CD5– DC3.
@Oxygen saturation -SO2- between 90 and 94% or 0.5 to 3 L/min oxygen requirement at screening.
§Treated at the intensive care unit -ICU- or at a high-dependency unit.
$ Including coryza, headaches, nausea, fever, cough, sore throat, malaise, headaches, and muscle aches.
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endosomal compartments of pDCs (Moreno-Eutimio et al.,
2020; Onofrio et al., 2020; Kim and Shin, 2021; Gabriele et al.,
2021). A clinical study showed that loss-of-function variants in
X-linked TLR7 genes were associated with impaired type I and
II IFN responses in young males, suggesting that the difference
in TLR7 gene dosage between males and females could explain,
at least in part, the predisposition of males to developing severe
COVID-19 (van der Made et al., 2020).
Numerical changes in DC subsets were investigated as putative
factors influencing anti-SARS-CoV-2 responses, and various
authors demonstrated that DCs tend to decrease in COVID-
19 patients vs. healthy controls, but in some reports, data also
reached a statistical significance comparing more severe cases
with patients with a milder form of the disease (Matic et al., 2020;
Zhou R. et al., 2020; Buttenschön and Mattner, 2021; Kvedaraite
et al., 2021; Zingaropoli et al., 2021; Table 2).
A more detailed analysis of CD11c+ DCs
accumulation/decrease as a function of both age and severity
should be urgently performed in adult COVID-19 cases. In fact,
non-plasmacytoid DCs are reported as numerically stable in the
old people (Agrawal et al., 2017; Oh et al., 2019), but this trend
seems to be reverted in severe COVID-19 patients, although
an age specific stratification of the cases was not performed
(Table 2; Matic et al., 2020; Zhou R. et al., 2020; Buttenschön and
Mattner, 2021; Kvedaraite et al., 2021; Zingaropoli et al., 2021).
Intriguingly, similar data were obtained comparing children in
the acute phase of mild disease vs. their convalescent counterpart
(Neeland et al., 2021), thus in the case of younger patients, milder
disease is accompanied by CD11c+ DC fluctuations resembling
those observed in adult severe cases. On the contrary, the
contraction of CD11c+ DC pool was not documented comparing
adult patients with mild symptoms vs. convalescent subjects
(Neeland et al., 2021), and the same DC subset was even reported
as increased in mild/moderate patients vs. healthy controls
(Matic et al., 2020). Molecular mechanisms causing stability of
CD11c+ DCs in older subjects seem to be compromised in both
adults with severe disease and children with mild disease, and
deserve further investigation.
Instead, plasmacytoid DCs tend to decrease in aging (Agrawal
et al., 2017; Oh et al., 2019; Márquez et al., 2020b). A reduction in
the plasmacytoid DCs was also reported in COVID-19 patients
irrespective of severity (Table 2; Arunachalam et al., 2020; Matic
et al., 2020; Kvedaraite et al., 2021; Zingaropoli et al., 2021).
During physiological aging processes, DCs exhibit multiple
functional defects ranging from mitochondrial dysfunction to an
impairment in antigen uptake/presentation and altered cytokine
secretion (Giefing-Kröll et al., 2015; Agrawal et al., 2017;
Ventura et al., 2017; Oh et al., 2019; Salminen et al., 2019).
DCs showed some degree of immunophenotypic/functional
alteration also in COVID-19. CD11c+ cDCs in hospitalized
patients and convalescent (follow up) outpatients exhibited less
surface expression of the co-stimulatory molecule CD86 than
DCs in healthy subjects (Zhou R. et al., 2020; Buttenschön and
Mattner, 2021). Similarly, expression of CD86 and HLA-DR
was uniformly reduced on circulating DC precursor (pre-DC),
pre-DC2, CD5+ DC2, CD163- CD14- DC3, CD163- CD14+
DC3, and CD163+ CD14+ DC3 in ICU or high dependency
unit severe patients vs. healthy donors (Kvedaraite et al., 2021).
Also, cDCs in both hospitalized patients and convalescent (follow
up) outpatients showed resistance toward maturation stimuli,
and an impaired ability to produce type I IFNs which was
more prominent in hospitalized patients (Zhou R. et al., 2020;
Buttenschön and Mattner, 2021), recalling a similar panel of
IFN secretion defects documented in older individuals (Agrawal
et al., 2017). Instead, the ability to answer to type I IFN
signaling seemed to be preserved in COVID-19 patients, as
demonstrated by the expansion of cell surface receptor tyrosine
kinase (AXL) expressing fraction among DC1 pool and the
reduced expression of c-kit as measured in DC1 (Rhodes et al.,
2019; Kvedaraite et al., 2021). INF-signaling was also highly
activated in BAL DC1 (Kvedaraite et al., 2021). However, myeloid
DCs showed an impaired ability to answer to TLR stimulation
(Arunachalam et al., 2020).
Activation of peripheral blood plasmacytoid DCs was made
evident by the decreased expression of CD45RA in COVID-19
patients vs. healthy controls (Kvedaraite et al., 2021). Similarly,
a reactive response in COVID-19 patients BAL plasmacytoid
DCs was demonstrated by activation of cytokine and chemokine
signaling pathways at a transcriptional level (Kvedaraite et al.,
2021). However, another report documented an impairment
in plasmacytoid DC function, with a reduced production of
IFN-α and TNF-α after TLR stimulation (Arunachalam et al.,
2020). Plasmacytoid DCs showed less HLA-DR in ICU or
high dependency unit severe patients than in moderate cases
(Kvedaraite et al., 2021).
Monocytes and Macrophages
Alterations of monocyte phagocytic and cytokine secreting
functions were consistently documented in older individuals;
however, numerical fluctuations do not affect all monocyte
subsets. Based on the expression of the surface markers
CD14 and CD16, circulating monocyte can be dived into
three subsets: classical, intermediate, and non-classical
monocytes, with CD14 decreasing from classical to non-
classical subsets, and CD16 following an opposite expression
pattern (Ziegler-Heitbrock et al., 2010).
CD14+ CD16– classical monocyte numbers do not change
during aging, whereas CD14+ CD16+ non-classical monocytes
tend to increase with age (Ventura et al., 2017; Oh et al.,
2019; Feng et al., 2021). Despite these functional changes,
monocytes seem to be key determinants of sex associated
differences in immunosenescence, with a male superior ability
in mounting inflammatory responses. In fact, men exhibit more
chromatin accessibility at monocyte specific loci than women
(Márquez et al., 2020a).
A sex specific study demonstrated that both male and female
non-ICU patients exhibited a higher percentage of monocytes
than male and female controls, respectively (Takahashi et al.,
2020). While CD14+ CD16– classical monocyte frequency
was overlapping among groups, CD14lowCD16- non-classical
monocytes were detected with higher frequencies in non-
ICU male patients vs. both male controls and female patients
(Takahashi et al., 2020). However, such a gender related effect
on non-classical monocytes was lost in all the studies pooling
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male and female patients and controls together, leading to
inconsistent results ranging from the absence of observed
changes in monocyte frequency irrespective of severity to a
statistically significant reduction in the case of more serious
symptoms (Table 3). In addition, to explain the irreproducibility
of results for both classical and non-classical monocytes, age
dependent repercussions on monocyte dynamics in COVID-
19 should be taken into account in the case of severity-based
studies. In fact, lower percentages of both CD14+CD16– classical
and CD14lowCD16+ non-classical monocytes were encountered
in peripheral blood of infected children experiencing mild
symptoms vs. convalescent children sampled 4–7 weeks following
test results (Neeland et al., 2021).
The observed discrepancy among the available reports on
classical and non-classical monocytes may also be a consequence
of the lack of shared criteria to stratify SARS-CoV-2 infected
subjects according to severity (Table 3; Wilk et al., 2020; Zhou
R. et al., 2020; Kvedaraite et al., 2021; Neeland et al., 2021;
Zingaropoli et al., 2021). In addition, from a more technical point
of view, small differences in the immunophenotypic parameters
evaluated to define monocytic subsets may be appreciated and
may account for the lack of reproducibility of the observed
data (Table 3).
Data about intermediate monocytes are also conflicting,
requiring the inclusion of both gender- and age-related effects on
disease severity in the study design. Percentage of CD14+CD16+
intermediate monocytes were reported as augmented in both
male and female non-ICU patients vs. their sex matched
controls, with more statistically significant results obtained for
female subjects (Takahashi et al., 2020). On the contrary, a
reduction in the frequency of peripheral blood CD14+CD16+
intermediate monocytes was detected in children with mild
disease vs convalescent children sampled (Neeland et al., 2021).
As reported in Table 3, a lower frequency of CD14++CD16+
intermediate monocytes was demonstrated in a cohort of patients
with COVID-19 pneumonia vs. healthy donors (Zingaropoli
et al., 2021). Instead, CD14+CD16+ intermediate monocytes
were higher in both moderate and severe cases vs. healthy
controls (Kvedaraite et al., 2021). No statistically significant
difference was detected comparing contacts of SARS-CoV-2 cases
with severe, mild and asymptomatic patients (Carsetti et al.,
2020; Table 3). In none of these reports, a sex and age specific
analysis was performed (Carsetti et al., 2020; Kvedaraite et al.,
2021; Zingaropoli et al., 2021).
The effect of sex and age on COVID-19 patients’ monocyte
function was not dissected, although some preliminary data
explored the behavior of monocyte subsets according to severity.
As regards monocyte functionality, levels of CD14+CD16-
classical and CD14+CD16+ intermediate monocyte HLA-DR and
CD86 were reduced in ICU or high-dependency unit patients vs.
both healthy controls and moderate cases of the disease, whereas
the same markers were reduced on CD14lowCD16++ non-
classical monocytes in severe patients vs. subjects with moderate
disease only (Kvedaraite et al., 2021). Similar piece of evidence
as regards HLA-DR expression emerged in another study
(Arunachalam et al., 2020). Moreover, as previously observed
for the mDCs, also COVID-19 patients CD14+ monocytes
showed an impaired ability to answer to TLR stimulation,
reinforcing the idea of an impaired innate response during
COVID-19 disease (Arunachalam et al., 2020). However, classical
monocytes from severe (according to the National Early Warning
Score) COVID-19 cases showed type I IFN response, and
exacerbation of TNF/IL-1β-driven inflammation (Lee et al., 2020;
Kim C.W. et al., 2021). Consistently, in the lung environment,
both BAL macrophages from severe patients (Liao et al., 2020;
Kim C.W. et al., 2021) and airway macrophages from critical
(according to WHO guidelines) cases (Chua et al., 2020)
exhibited proinflammatory characteristics (Chua et al., 2020; Liao
et al., 2020; Kim C.W. et al., 2021).
Neutrophils
The neutrophil number is preserved during aging, but the
reduction in CD16 expression accounts for a notable functional
decline (Ventura et al., 2017; Oh et al., 2019; Salminen et al.,
2019; Cunha et al., 2020; Zimmermann and Curtis, 2020). Also,
using animal models it was documented that lung neutrophils
exhibit signs of exhaustion due to exposure to inflammatory
mediators associated with advancing age (Ventura et al., 2017;
Domingues et al., 2020).
Analysis of peripheral blood composition in COVID-19 cases
revealed that in ICU patients neutrophil count was higher than
that observed in non-ICU patients (Wang D. et al., 2020),
and that neutrophil count was higher in deceased patients vs.
survivors (Du et al., 2020; Fu Y. Q. et al., 2020).
SSChiCD16+ low density neutrophils, including migrating
cells and immature elements in both healthy conditions and
inflammation (Silvestre-Roig et al., 2019; Hassani et al., 2020),
seem to exert a protective role in both adults and children. In
fact, their accumulation was documented in PCR-negative adults
and children exposed to SARS-CoV-2 in the household, with
higher percentages recorded when sampling happened during the
convalescence period (up to 7 weeks after positive test results) vs.
exposure during the acute phase (Neeland et al., 2021).
No changes were recorded for neutrophils and activated
CD63+ neutrophils comparing both adult SARS-CoV-2
positive and adult SARS-CoV-2 exposed subjects in acute and
convalescent phase (Neeland et al., 2021). Instead, an increase in
the percentage of CD63+ neutrophils was detected comparing
infected children experiencing mild symptoms with both
convalescent children sampled 4–7 weeks following test results
and PCR negative children exposed to SARS-CoV-2 through
household close contact with a positive in the acute phase
(Neeland et al., 2021). Since expression of CD63 on neutrophils
is a sign of activation (Silvestre-Roig et al., 2019), it would be
worth deepening if more older individuals may experience
a difference in neutrophil degranulation in comparison with
younger patients, and if such a difference may be related to
COVID-19 severity.
Myeloid Derived Suppressor Cells
(MDSCs)
Myeloid-derived suppressor cells (MDSCs) are cells of the
myeloid lineage exerting a suppressive function on other
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TABLE 3 | Observed fluctuation in monocytic subsets in adult COVID-19 patients.
Monocytes Observation Analyzed patients Compared group(s) References
Classical CD14++CD16- monocytes Reduction (%) Hospitalized HD Zhou R. et al., 2020
Reduction (%) Convalescent HD Zhou R. et al., 2020
No change (%) Pneumonia HD Zingaropoli et al., 2021
No change (%) Mild$ Convalescent Neeland et al., 2021
Classical CD14+CD16- monocytes No change (%) Severe& Mild* Carsetti et al., 2020
No change (%) Severe& Asymptomatic Carsetti et al., 2020
No change (%) Severe& Contacts+ Carsetti et al., 2020
No change (%) Mild* Asymptomatic Carsetti et al., 2020
No change (%) Mild* Contacts+ Carsetti et al., 2020
No change (%) Asymptomatic Contacts+ Carsetti et al., 2020
CD14+CD16+ non-classical monocytes Reduction (%) Pneumonia HD Zingaropoli et al., 2021
Reduction (%) ARDS Non-ARDS Zingaropoli et al., 2021
CD14-CD16+ non-classical monocytes Reduction (%) Severe& Mild* Carsetti et al., 2020
Reduction (%) Severe& Asymptomatic Carsetti et al., 2020
Reduction (%) Severe& Contacts Carsetti et al., 2020
No change (%) Mild* Asymptomatic Carsetti et al., 2020
No change (%) Mild* Contacts+ Carsetti et al., 2020
No change (%) Asymptomatic Contacts+ Carsetti et al., 2020
CD14lowCD16+ non-classical monocytes Reduction (%) Mild$ Convalescent Neeland et al., 2021
CD14lowCD16++ non-classical monocytes Reduction (%) Severe§ HD Kvedaraite et al., 2021
CD14++CD16+ intermediate monocytes Reduction (%) Pneumonia HD Zingaropoli et al., 2021
CD14+CD16+ intermediate monocytes Increase (%) Moderate@ HD Kvedaraite et al., 2021
CD14+CD16+ intermediate monocytes Increase (%) Severe§ HD Kvedaraite et al., 2021
CD14+CD16+/– intermediate monocytes No change (%) Severe& Mild* Carsetti et al., 2020
No change (%) Severe& Asymptomatic Carsetti et al., 2020
No change (%) Severe& Contacts+ Carsetti et al., 2020
No change (%) Mild* Asymptomatic Carsetti et al., 2020
No change (%) Mild* Contacts+ Carsetti et al., 2020
No change (%) Asymptomatic Contacts+ Carsetti et al., 2020
(%), as frequency values; HD, healthy donors; ARDS, acute respiratory distress syndrome, asymptomatic patients who tested positive but had no symptoms.
$ Including coryza, headaches, nausea, fever, cough, sore throat, malaise, headaches, and muscle aches.
§Treated at the intensive care unit -ICU- or at a high-dependency unit.
@Oxygen saturation -SO2- between 90 and 94% or 0.5 to 3 L/min oxygen requirement at screening.
&Pneumonia (fever, cough, dyspnoea, fast breathing) plus one of the following: respiratory rate > 30 breaths/min; severe respiratory distress; or SpO2 < 90% on room air.
*Patients requiring no hospitalization and experiencing symptoms like with fever, myalgia, and fatigue without obvious chest high resolution computed tomography
findings for COVID-19.
+Contacts of SARS-CoV-2 confirmed cases who were negative by qPCR.
immune cells through numerous molecular mechanisms
(Salminen et al., 2019). MDSCs can be divided into two main
branches, CD11b+CD33+CD15+CD14-HLA-DR- granulocytic
MDSCs and CD11b+CD33+CD15-CD14+HLA-DRlo/-
monocytic MDSCs, together with a further subset devoid
of both granulocytic and monocytic markers (Salminen
et al., 2019; Bergenfelz and Leandersson, 2020; Kramer
and Abrams, 2020). Only the proportion of granulocytic
MDSCs is reported as increased during aging (Salminen et al.,
2019). However, to the best of our knowledge, no sexual
dimorphism was described about distribution and function of
MDSCs in individuals.
Expansion of functional granulocytic MDSCs was
documented in COVID-19 patients vs. healthy donors, and
was particularly evident in severe cases (Agrati et al., 2020)
and in ICU patients (Sacchi et al., 2020). The percentage of
monocytic myeloid derived suppressor cells (M-MDSCs) was
higher in hospitalized patients vs. both convalescent (follow up)
outpatients and healthy donors (Zhou R. et al., 2020; Buttenschön
and Mattner, 2021).
ACQUIRED IMMUNITY: T CELLS
Among components of both innate and adaptive immune system,
there seems to be more coherence in the information on T cell
responses observed during COVID-19 disease. A central object
of study in several reports, the information obtained to date on
changes in cellular immunity, and discussed below in relation to
age and sex, may help us to better understand the differences in
infection outcomes observed.
Functionally, T cells are considered naïve until they encounter
their cognate antigen in the periphery, and phenotypically they
are CCR7+CD45RA+CD28+CD27+ cells. In the context of
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SARS-CoV-2 infection, after encountering novel viral antigens,
naïve T cells expand and differentiate into different types
of effector cells, whose protective roles encompass TH-cell-
mediated activation of B cells to produce virus-specific antibodies
and elimination of virus-infected cells by CTLs. SARS-CoV-
2-specific T cells have been reported in COVID-19 patients
(Braun et al., 2020; Sekine et al., 2020). Following activation,
the chemokine receptor CXCR3 is rapidly induced on naïve
cells T cells and preferentially remains highly expressed on
TH1 cells and effector CD8+ T cells (Groom and Luster,
2011). In contrast to innate immune cells, T cells develop a
memory for repeated challenges. Indeed, following clearance of
pathogen, most of effector T cells die but a small subset further
differentiates into long-lived memory T cells that provide long-
term protective immunity (Mahnke et al., 2013). So, in the event
of a second contact with the virus, memory T cells rapidly
mature into effector cells, responding to infection. Previously
studies in mice have highlighted the importance of specific cell-
mediated memory in protection from SARS-CoV-1 (Zhao J.
et al., 2010; Channappanavar et al., 2014). It was shown that in
some individuals exposure to SARS-CoV-2 has induced virus-
specific T cell responses even in the absence of seroconversion,
suggesting that individuals with no detectable antibodies may
nonetheless be protected by cellular immunity (Gallais et al.,
2021). This raises the question of whether T-cell responses
would be more sensitive indicators of SARS-Co-V-2 exposure
than antibody quantification of anti-nucleoprotein and anti-
spike IgG or IgA levels in peripheral blood. However, individual
variability in immune response must be taken into account,
especially in view of the profound immune changes observed
with aging. Thus, a thorough understanding of the role of T cells
in the immune response to SARS-CoV-2 and how aging may
impair their responsiveness is essential to gain insights into both
the individual ability to respond to the first infection and the
quality, magnitude, and durability of protective immunity against
reinfection with SARS-CoV-2.
As this is an emerging pathogen to which the human
population has never previously been exposed, although cross-
reactive T cell recognition between circulating ‘common cold’
coronaviruses and SARS-CoV-2 has been suggested (Grifoni
et al., 2020), the key step in the immune response is undoubtedly
its recognition by naïve, and not memory, T cells. Early and
efficient virus-specific CD8+ T cell responses and CD4+ T cell-
dependent antibody responses of sufficient magnitude against
SARS-CoV-2 would probably be protective (Zhao J. et al., 2016).
However, age-related alterations in the T cell compartment could
lead to a failure to develop protective immunity in old patients. As
previously mentioned, thymic involution is the main driver of the
reduced absolute numbers and percentages of peripheral naïve
T cells observed in old individuals. Their homeostatic peripheral
proliferation is thought to compensate for this loss but can lead
to the outgrowth of certain T cell clones at the expense of others,
with shrinkage of the T cell repertoire. As a consequence, the
pool of naïve T cells decreases with age with quantitatively and
qualitatively impairs de novo CD8+ T-cell responses (Briceño
et al., 2016). In parallel, there is an expansion of the memory
T cell pool, probably due to chronic or persistent infections,
most commonly with Cytomegalovirus, which cause specific
T cells to clonally expand through repetitive stimulation. One
of the phenotypic characteristics of these persistent stimulated
T cells is the progressive downregulation of the costimulatory
receptor CD28 that is definitively lost in terminally differentiated
T cells (Pangrazzi et al., 2020). These CD28– senescent T cells
are characterized by low proliferative capacity, shortening of
telomeres and express senescent markers, such as programmed
cell death protein 1 (PD-1). These age-associated changes in
T cell subset distribution, especially in CTL, critically affect
primary immune responses against viruses (Pawelec, 2018; Aiello
et al., 2019). A recent study performed by our group has
highlighted differences in the lymphocyte subset distribution in
both helper and cytotoxic compartments between females and
males during aging (Ligotti et al., 2021). These immune gender
differences during aging and in case fatality rates in COVID-19
disease support the need to incorporate investigation of biological
factors underlying differences in immune responses to SARS-
CoV-2 between females and males in order to identify targeted
therapeutic interventions aimed to improve antiviral immune
function (Bunders and Altfeld, 2020).
Despite differences in patient stratification, several studies
have reported lymphopenia, affecting all lymphocyte subsets, in
a significant proportion of patients with severe diseases, both
males and females, such that it can be considered, together with
hyper-cytokinaemia, a signature for severe COVID-19 infection
and pneumonia (Bermejo-Martin et al., 2020). The occurrence of
lymphopenia (lymphocyte count < 0.8–1.1 × 109/L, depending
on the cut-off value used) was reported in 85% (Yang et al.,
2020), 72.3% (Liu K. et al., 2020; Zhan et al., 2020), 66.7% (Meng
Y. et al., 2020), 63% (Huang et al., 2020), and 42.9% (Chen
G. et al., 2020) of infected cases, with the highest percentages
observed in critically ill patients. Specifically, significant decreases
in absolute T cell counts, TH cells, and CTL cells were observed
in the COVID-19 patients compared to healthy controls, but
accentuated in the severe cases (Cui et al., 2020; Wang F. et al.,
2020), indicating SARS-CoV-2 infection has a negative impact on
T-cell mediated immunity. In older COVID-19 patients (median
age 71 years), low lymphocytes count was a strong predictor
of poor outcome while high lymphocyte levels were predictive
of better outcome (Wang L. et al., 2020). This peripheral
lymphopenia could reflect the recruitment of lymphocytes from
the blood to the infected site in response to combinations of
different chemokines expressed by airway and alveolar blood
vessel endothelial cells (Alon et al., 2021). A meta-analysis of
the mean difference in lymphocyte counts at admission between
patients with good and with poor COVID-19 outcomes has
shown that lymphopenia was significantly associated with severe
COVID-19 and this association was affected by age but not by
sex (Zhao Q. et al., 2020). However, some studies have suggested
that the male sex is inversely associated with lymphocyte count,
especially in patients with comorbidity (Meng Y. et al., 2020; Qin
et al., 2020), although not always confirmed (Zhao G. et al., 2021).
In the peripheral blood of SARS-CoV-2-infected patients, both
CD4+ and CD8+ T cell blood counts are dramatically decreased
compared to healthy controls, with the highest evidence observed
in severe cases (de Candia et al., 2021). Nevertheless, male
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COVID-19 patients have shown lower CD4+ T cell and higher
CD8+ T cell proportions than female patients, indicating a
possible more severe immune dysregulation (Zhao G. et al., 2021;
Table 4).
Analysis of T cells in BAL of COVID-19 patients has identified
lower CD8+ T cell levels in patients with severe infection
than in patients with moderate infection, apparently against the
hypothesis of sequestration on the site of infection. On the other
hand, CD8+ T cells in BAL from patients with moderate infection
have shown upregulation of genes involved in differentiation,
activation, migration and cytokine-related pathways compared
with severe cases (Liao et al., 2020; Table 4).
Despite the absolute counts of CD8+ T cells decreased,
analysis of T cell activation has revealed a significant increment
in the frequency and absolute numbers of activated (co-
expressing HLA-DR and CD38) CD8+ T cells and increased
multiple cytotoxic granules expression in COVID-19 pneumonia
patients (De Biasi et al., 2020; Song et al., 2020; Chen
Q. et al., 2021). Analysis of post-mortem lung tissue from
16 patients with COVID-19 has correlated the presence of
abundant infiltrating activated CD8+ T cells (CD38, GZMA,
GZMB, CCR5) with a specific immunopathological pattern
characterized by low local expression of interferon stimulated
genes, low viral counts, massive lung damage, and late death
(Nienhold et al., 2020). Based on these pieces of evidence,
it has been suggested that this aberrant activation of CTLs
in patients with severe COVID-19 disease could play an
important role in the pathogenesis of SARS-CoV-2 infection
(Song et al., 2020). However, CD8+ T cells from older
COVID-19 patients with mild disease do not show increased
production of perforin and granzymes, probably due to high
background levels of cytotoxic molecules (Westmeier et al., 2020;
Table 4).
A significant increment in the frequency, but not in the
absolute count, of activated CD4+ T cells or exhausted/senescent
(PD-1+CD57+) peripheral CD4+ and CD8+ T cells was also
observed (De Biasi et al., 2020). When gender differences
were considered, this increase in percentages of activated and
terminally differentiated T cells being significant in female but
not in male patients compared with healthy controls, suggesting
a more robust T cell response among female patients. Although
these differences were observed in both CD4+ and CD8+ T
cells, more significant differences were found in the cytotoxic
subset (Chen and John Wherry, 2020; Takahashi et al., 2020;
Table 4). The implications and mechanisms underlying increased
CD8+ activity are unknown in the context of this novel virus
but may play a role in driving the immunopathogenesis of
COVID-19.
The characterization of the T cell subsets in a cohort of
39 COVID-19 with a median age of 64 years (range 35–
94) has revealed that a decrease in both the percentage
and the absolute number of naïve CD45RA+CCR7+ CD8+ T
cells and in the absolute number of naïve CD45RA+CCR7+
CD4+ T cells (De Biasi et al., 2020; Belaid et al., 2021).
A similar trend was observed as CCR7+CD45RA- central
memory T cells, while the percentage, but not the absolute
number of terminal effector CCR7-CD45RA+ T cells was higher,
although with a decreased proliferation index suggesting a lack
of clonal expansion after activation (De Biasi et al., 2020).
Compared to hospitalized COVID-19 patients during acute
disease, patients at 3–6 months of convalescence showed higher
proportions of CD4+ and CD8+ CCR7–CD45RA+ effector T
cells and reduced expression of the proliferation marker Ki-
67. In male patients, disease progression was associated with
higher age and lower CD8+ T cell response (IFN-γ production
and activation), while these correlations were not seen in
females. On the contrary, female patients showed greater T cell
response, characterized by higher percentages of activated and
terminally differentiated CD8+ T cells (Takahashi et al., 2020;
Table 4).
CD4+ and CD8+ T cells in acute COVID-19 patients
showed a substantial reduction of CXCR3 and CXCR5
expression, irrespective of disease severity, that is recovered
upon convalescence (Shuwa et al., 2021). In another study,
when compared to their younger counterparts and to age-
matched healthy donors, over 80-year-olds COVID-19
patients showed a more pronounced reduction in CD8+
T cell count. Moreover, percentages of naïve CD45RO-
CCR7+ CD28+ CD8+ T cells were markedly reduced in 29-
to 79-year-old group of COVID-19 patients, suggesting an
ongoing cytotoxic response during SARS-Cov-2 infection,
but these differences were not evident in the over 80 group,
probably due to the reduced pool of naïve T cells in the
old individuals. Likewise, the increase in CD8+ CD45RO-
CCR7- CD28- terminally differentiated effector and CD45RO+
CCR7- CD28- effector memory T cells was more evident
in the younger group than in the 80- to 96-year-old age
group (Westmeier et al., 2020). CD4+ memory responses to
SARS-CoV-2 were detected in 100% of recovered patients,
while 70% established CD8+ memory responses. Most of
T cell reactivity to the viral Spike protein was dependent
on CD4+ T cells and these responses were correlated with
anti-SARS-Cov-2 IgG and IgA titres in COVID-19 cases
(Grifoni et al., 2020). A sophisticated and detailed analysis
of T cell immunophenotype in COVID-19 patients has
revealed the heterogeneity of the immune response to SARS-
CoV-2 infection ranging from robust CD8+ and/or CD4+
T cell activation and proliferation to minimal detectable
responses compared to healthy donors (Mathew et al.,
2020). This suggests that the relationship between acquired
immunity and COVID-19 pathogenesis is complex and
must be taken into account in the design of therapies and
vaccines (Table 4).
Most analyses were not stratified by gender. It therefore
remains to be established whether cell-mediated immune
response may differ between the two sexes and whether this
affects the durability of immunity and vaccine approaches.
Moreover, given the multitude of well-documented age-
related changes in the composition and responsiveness of
the acquired immune system, further comparative studies
between young and old are needed to investigate differences
in virus-specific T cells responses. Indeed, any intervention
aimed at improving immune status in old individuals
should be targeted and individualized, especially in a context
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TABLE 4 | Observed fluctuation in T cell subsets in adult COVID-19 patients.
T cell subsets Observation Analyzed patients Compared
group(s)
References
Total CD3+CD19– T lymphocyte Reduction (%) Deceased Survivors Cui et al., 2020
Reduction (#) Deceased Survivors Cui et al., 2020; Belaid et al., 2021
Reduction (%) Cases Recovered Mathew et al., 2020
Reduction (%) Cases HD Mathew et al., 2020
Reduction (#) Severeη Mildζ /moderateθ Song et al., 2020; Belaid et al., 2021
No change (%) Severeη Mildζ Song et al., 2020
CD3+CD4+ Helper T lymphocyte Reduction (%) Deceased Survivors Cui et al., 2020
Reduction (#) Deceased Survivors Cui et al., 2020
Reduction (#) Pneumonia patients HD Wang F. et al., 2020
Reduction (#) Severeη Mildζ /moderateθ Song et al., 2020; Wang F. et al., 2020;
Belaid et al., 2021; Taghiloo et al., 2021
No change (%) Severeη HD De Biasi et al., 2020
Reduction (#) Severeη HD De Biasi et al., 2020
Reduction (%) Cases Recovered Mathew et al., 2020
Reduction (%) Cases HD Mathew et al., 2020
No change (%) Severeη Mildζ Song et al., 2020
CD3+CD8+ Cytotoxic T lymphocyte Reduction (%) Deceased Survivors Cui et al., 2020
Reduction (#) Deceased Survivors Cui et al., 2020; Belaid et al., 2021
Reduction (#) Pneumonia patients HD Wang F. et al., 2020
Reduction (#) Severeη Mildζ /moderateθ Song et al., 2020; Wang F. et al., 2020;
Belaid et al., 2021; Taghiloo et al., 2021
No change (%) Severeη HD De Biasi et al., 2020
Reduction (#) Severeη HD De Biasi et al., 2020
Reduction (%) Cases Recovered Mathew et al., 2020
Reduction (%) Cases HD Mathew et al., 2020
No change (%) Severeη Mild Song et al., 2020
CCR7+CD45RA+CD28+CD27+ CD4+ naïve No change (%) Severeη HD De Biasi et al., 2020
Reduction (#) Severeη HD De Biasi et al., 2020
CCR7-CD45RA+CD28+CD27+/- CD4+ central memory No change (%) Severeη HD De Biasi et al., 2020
Reduction (#) Severeη HD De Biasi et al., 2020
No change (%) Severeη HD De Biasi et al., 2020
Reduction (#) Severeη HD De Biasi et al., 2020
CCR7-CD45RA+CD28-CD27+/- CD4+ terminal effector Increase (%) Severeη HD De Biasi et al., 2020
No change (#) Severeη HD De Biasi et al., 2020
CCR7-CD45RA+CD27- CD4+ naïve terminal effector Increase (%) Cases Recovered Mathew et al., 2020
Increase (%) Cases HD Mathew et al., 2020
CD38+HLA-DR+ CD4+ activated No change (#) Severeη HD De Biasi et al., 2020
Increase (%) Severeη HD De Biasi et al., 2020
Increase (%) Mildζ HD Song et al., 2020
Increase (%) Severeη HD Song et al., 2020
Increase (%) Deceased Survivors Belaid et al., 2021
Increase (%) Cases Recovered Mathew et al., 2020
Increase (%) Cases HD Mathew et al., 2020
No change (%) Severeη Mildζ /moderateθ Song et al., 2020; Belaid et al., 2021
PD-1+CD57+ CD4+ exhausted/senescent Increase (%) Severeη HD De Biasi et al., 2020
No change (#) Severeη HD De Biasi et al., 2020
CCR7+CD45RA+CD28+CD27+ CD8+ naïve Reduction (%) Severeη HD De Biasi et al., 2020
Reduction (#) Severeη HD De Biasi et al., 2020
CCR7+CD45RA+ CD8+ naïve Reduction (%) Severeη Mildζ /moderateθ Belaid et al., 2021
Reduction (%) Deceased Survivors Belaid et al., 2021
CCR7-CD45RA+CD28+CD27+/- CD8+ central memory Reduction (%) Severeη HD De Biasi et al., 2020
Reduction (#) Severeη HD De Biasi et al., 2020
(Continued)
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TABLE 4 | Continued
T cell subsets Observation Analyzed patients Compared
group(s)
References
CCR7-CD45RA-CD28+/-CD27+/- CD8+ effector memory No change (%) Severeη HD De Biasi et al., 2020
No change (#) Severeη HD De Biasi et al., 2020
CCR7-CD45RA-CD8+ effector memory Increase (%) Deceased Survivors Belaid et al., 2021
CCR7-CD45RA+CD28-CD27+/- CD8+ terminal effector Increase (%) Severeη HD De Biasi et al., 2020
No change (#) Severeη HD De Biasi et al., 2020
CCR7-CD45RA+CD27- CD8+ naïve terminal effector Increase (%) Cases Recovered Mathew et al., 2020
Increase (%) Cases HD Mathew et al., 2020
CD38+HLA-DR+ CD8+ activated Increase (%) Severeη HD De Biasi et al., 2020
Increase (#) Severeη HD De Biasi et al., 2020
Increase (%) Mildζ HD Song et al., 2020
Increase (%) Severeη HD Song et al., 2020
Increase (%) Deceased Survivors Belaid et al., 2021
Increase (%) Severeη Mildζ Song et al., 2020
Increase (%) Cases Recovered Mathew et al., 2020
Increase (%) Cases HD Mathew et al., 2020
No change (%) Severeη Mildζ /moderateθ Belaid et al., 2021
PD-1+CD57+ CD8+ exhausted/senescent Increase (%) Severeη HD De Biasi et al., 2020
No change (#) Severeη HD De Biasi et al., 2020
BAL T cells Reduction (%) Severeη /Criticalι Moderateθ Liao et al., 2020
Increase (%) Moderateθ HD Liao et al., 2020
T cell subset, peripheral blood T cell subset analyzed in the reported studies; (%), as frequency values; (#), as absolute number; Cases, COVID-19 patients (irrespective
of severity); HD, healthy donors; Recovered, non-hospitalized subjects who had recovered from SARS-CoV-2 infection.
ζPatients with or without pneumonia admitted to general wards not requiring intensive care.
ηPatients experiencing the following: respiratory failure, respiratory rate > 30 bpm, oxygen saturation < 93% at rest, arterial partial pressure of oxygen (PaO2)/fraction of
inspired oxygen (FiO2) (PaO2/FiO2) ratio < 300 mmHg.
θFever, respiratory symptoms, and pneumonia evidenced by computed tomography.
ιAny of the following: requirement for mechanical ventilation, shock, or concomitant organ failure.




B cells function in the humoral immunity component of
the acquired immune system, producing antibodies that are
not secreted, but inserted into the plasma membrane where
they serve as a part of B-cell receptors. When a naïve or
memory B cell is activated by an antigen, it proliferates and
may differentiate into a short living plasmablast, or a long
living plasma cell (both known as antibody-secreting cells –
ASCs) – it is not known if plasma cells represent a further
maturation step of early plasmablasts (Jourdan et al., 2009;
Khodadadi et al., 2019).
Immunosenescence impacts B lymphocytes at multiple levels.
During aging, B cells show a decline in the number of
newly produced clones flanked by a contraction of their
repertoire, producing a variable level of accumulation of
memory cells and an increase in the appearance of signs
of exhaustion (Giefing-Kröll et al., 2015; Aiello et al., 2019;
Crooke et al., 2019; Ma et al., 2019; Lian et al., 2020).
The age associated decline in the amount of B cells appears
more dramatic in men than in women, and menopausal
related changes in B cell numbers are counteracted by
hormone replacement therapy (Giefing-Kröll et al., 2015;
Márquez et al., 2020a). Also, during aging women exhibit more
pronounced chromatin accessibility at B cell loci than older male
individuals, who suffer a downregulation of B cell-specific genes
(Márquez et al., 2020a).
Changes in B cell distribution during COVID-19 affect the
quality and intensity of SARS-CoV-2 elicited immune response,
accounting for infection resolution and persistence of symptoms
after viral clearance (Huang et al., 2021; Long et al., 2021; Shuwa
et al., 2021; Wheatley et al., 2021). This was demonstrated also
from a functional point of view, with both somatic hypermutation
in B cell receptor (BCR) and higher antibody titres correlating
with disease severity (Schultheiß et al., 2020; Okba et al., 2020).
Thus, COVID-19 related B lymphocyte alterations determine
not only disease severity but also the entity of long-term
consequences and may have potential prognostic applications
(Detsika et al., 2021; Kim C.W. et al., 2021; Kos et al., 2021;
Shuwa et al., 2021).
Total B Cells
During aging a contraction of both number and percentage of
peripheral B cells was described multiple times, with a more
visible reduction in older males (Bulati et al., 2014; Giefing-
Kröll et al., 2015; Hazeldine and Lord, 2020; Lian et al., 2020;
Márquez et al., 2020b,a; Vellas et al., 2020). In COVID-19
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the analysis of B cell changes according to a gender-based
stratification of patients revealed that only the frequency of B
cells was higher in both non-ICU male and female patients than
in controls, reaching a statistically significant result narrowly
when the comparison was performed between the two female
groups (Takahashi et al., 2020). However, no sex or age
correlated differences in B cell counts of COVID-19 patients
were documented (Jurado et al., 2020; Takahashi et al., 2020;
Jin et al., 2021).
In gender pooled reports about the total number and
percentage of B cells in COVID-19+ subjects, data vary
from a study to another on the basis of both the choice
of the confronted parameter (number of cells rather than
percentage) and the adopted criteria to stratify the analyzed
subjects according to severity (Carsetti et al., 2020; Sosa-
Hernández et al., 2020; Detsika et al., 2021; Kos et al., 2021;
Shuwa et al., 2021; Xiong et al., 2021). Numerous papers
are available documenting the invariability, the decrease and
the increase of B cell numbers and frequency in various
categories of COVID-19 patients (Table 5). This lack of
homogeneity mirrors the absence of an agreement about the
stratification of COVID-19 cases according to severity. In
addition, the selected statistical analysis strategy, especially
in the presence of multiple comparisons, may “mask” some
statistically significant results, requiring a larger sample size
or a different statistical approach to reveal relevant differences
among the compared categories (Jurado et al., 2020; Sosa-
Hernández et al., 2020; Woodruff et al., 2020; d’Alessandro
et al., 2021; Newell et al., 2021; Shuwa et al., 2021). As a
result, the abundance of confounding reports slows down the
extrapolation of prognostic and predictive pieces of information
from published reports.
Despite these contradictory data, a recent metanalysis
demonstrated a statistically significant decrease in B
cells in severe disease cases vs. non severe disease group
(Akbari et al., 2020).
TABLE 5 | Observed fluctuation in B cells in adult COVID-19 patients.
B cells Observation Analyzed patients Compared group(s) References
Total peripheral blood B cells No change (#) Intubated Non-intubated Detsika et al., 2021
No change (#) Intubated (admission) Intubated (recovery) Detsika et al., 2021
No change (#) Severe+ (admission) Mild* (admission) Jurado et al., 2020
No change (#) Moderate& (admission) Mild* (admission) Jurado et al., 2020
No change (#) Severe+ (admission) Moderate& (admission) Jurado et al., 2020
No change (#) Critical§ SevereŁ Liu Y. et al., 2021
No change (#) Cases HD d’Alessandro et al., 2021
No change (#) Severe> Non-severe< d’Alessandro et al., 2021
Reduction (#) Deceased Survivors Cantenys-Molina et al., 2021; Kos
et al., 2021; Xiong et al., 2021
Reduction (#) Critical§ Moderate@ Liu Y. et al., 2021
Reduction (#) Severe◦ Non-severe∧ Zhang W. et al., 2020
Reduction (#) Compositeα Non-compositeβ Zhang W. et al., 2020
Increase (#) ICU NCU Kos et al., 2021
Increase (#) ICU NCU (non-COVID-19) Kos et al., 2021
Increase (#) ICU ICU (non-COVID-19) Kos et al., 2021
No change (%) Convalescent HD Newell et al., 2021
No change (%) Severe> Non-severe< d’Alessandro et al., 2021
No change (%) Severe+ (admission) Mild* (admission) Jurado et al., 2020
No change (%) Severe+ (discharge) Mild* (discharge) Jurado et al., 2020
No change (%) Moderate& (admission) Mild* (admission) Jurado et al., 2020
No change (%) Moderate& (discharge) Mild* (discharge) Jurado et al., 2020
No change (%) Severe+ (admission) Moderate& (admission) Jurado et al., 2020
No change (%) Severe+(discharge) Moderate&(discharge) Jurado et al., 2020
Reduction (%) ICU NCU Kos et al., 2021
Reduction (%) ICU NCU (non-COVID-19) Kos et al., 2021
Reduction (%) ICU ICU (non-COVID-19) Kos et al., 2021
Reduction (%) Severeγ Mildδ Shuwa et al., 2021
Reduction (%) Severeγ Moderateε Shuwa et al., 2021
Reduction (%) Severeζ Asymptomatic Carsetti et al., 2020
Increase (%) Cases HD Woodruff et al., 2020
Increase (%) Severeη Mild/moderateθ Sosa-Hernández et al., 2020
Increase (%) Cases Convalescent Files et al., 2021
(Continued)
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TABLE 5 | Continued
B cells Observation Analyzed patients Compared group(s) References
Bone marrow and spleen total B cells Reduction (#) Deceased Controls$ Ihlow et al., 2021
BAL B cells Reduction (%) Severe/ Mild/ Kim C.W. et al., 2021
Increase (%) Mild/ HD/ Kim C.W. et al., 2021
Increase (#) Severe/ Mild/ Kim C.W. et al., 2021
Increase (#) Severe/ HD/ Kim C.W. et al., 2021
BAL, bronchoalveolar lavage; (%), as frequency values; (#), as absolute number; Cases, COVID-19 patients (irrespective of severity); ICU, intensive care unit patients; HD,
healthy donors; NCU, normal care unit patients; NCU (non-COVID-19), normal care unit patients treated for other reasons than COVID-19; ICU (non-COVID-19), intensive
care unit patients treated for other reasons than COVID-19; asymptomatic, patients who tested positive but had no symptoms.
*Clinical mild symptoms with no abnormal radiological findings.
+Non-severe pneumonia.
&As defined by the physician in charge or meeting at least one of the following criteria: acute respiratory distress, shock, admission to the intensive care unit -ICU-;
patients with a fatal outcome were also included in this group.
§With any of the following: (1) respiratory failure requiring mechanical ventilation; (2) shock; or (3) other organ failure requiring monitoring and treatment in ICU.
Ł Individuals experiencing any of the following: (1) respiratory distress, respiratory rate ≥ 30 breaths/min; (2) oxygen saturation on room air ≤ 93% at rest; (3) oxygenation
index PaO2/FIO2 ≤ 300 mmHg; or (4) lung infiltrates > 50% within 24–48 h.
$Age matched subjects who died for cardiac conditions.
> ICU admission, mechanical ventilation, or high-flow oxygen therapy.
<Patients who were not experiencing ICU admission, mechanical ventilation, or high-flow oxygen therapy.
@Fever and other respiratory tract symptoms with pneumonia on chest computed tomography.
◦Respiratory rate ≥ 30/min, a pulse oxygen saturation ≤ 93% on room air, oxygenation index ≤ 300 mmHg, respiratory failure for which invasive ventilation was necessary,
signs of shock (circulatory failure), organ failure and ICU care.
∧Mild symptoms + normal radiology findings in both lungs, and fever, cough, and other respiratory symptoms + radiological signs of pneumonia.
αPatients experiencing admission to the ICU, mechanical ventilation, or death.
βPatients who did not experience admission to the ICU, mechanical ventilation, or death.
γPatients with > 10L or 60% supplemental oxygen, managed in ICU.
δPatients with < 3L or 28% supplemental oxygen.
εPatients with < 10L or <60% supplemental oxygen, requiring non-invasive ventilation (NIV) or continuous positive airway pressure (CPAP).
ζPatients with clinical signs of pneumonia with one of the following: respiratory rate > 30 breaths/min, severe respiratory distress, or SpO2 < 90% on room air.
ηPatients experiencing the following: respiratory failure, respiratory rate > 30 bpm, oxygen saturation < 92% at rest, arterial partial pressure of oxygen (PaO2)/fraction of
inspired oxygen (FiO2) (PaO2/FiO2) ratio < 300 mmHg.
θFever, signs of airway disease, with or without a tomographic image indicating pneumonia.
/No stratification criteria neither statistically significance data provided.
Transitional and Naïve B Cells
Immunosenescence is associated with a decrease in CD27-
IgD+ naïve B lymphocytes and the consequential reduction in
B cell repertoire diversity (Cancro et al., 2009; Crooke et al.,
2019; Ma et al., 2019; Oh et al., 2019). To the best of our
knowledge, no naïve B cell specific molecular and numerical
analysis was performed as a function of age and gender in
COVID-19, and naïve B cells are reported as mostly unchanged
in their frequency irrespective of disease severity (Table 6; Sosa-
Hernández et al., 2020; Long et al., 2021; Shuwa et al., 2021).
However, frequency of CD19+CD27loIgM+IgD+ mature naïve
B cells seemed to be correlated with seroconversion, considering
that percentages recorded for this B subset were higher in
patients with high seroconversion index values vs. subjects
with low seroconversion index values (seroconversion indices
were estimated by summing the Z-scores for each of the four
seroconversion assays used by the authors – see Galbraith et al.,
2021 for details) (Galbraith et al., 2021).
On the contrary, transitional B cells tend to remain stable in
adults (Perez-Andres et al., 2010; Blanco et al., 2018) and may
exert immunomodulatory functions producing IL-10 (Zhou Y.
et al., 2020). In COVID-19 literature, data about transitional
B cell frequency according to disease severity are not fully
homogeneous, despite the majority of data suggest that a
reduction in transitional B cells may contribute to more severe
disease (Table 6; Sosa-Hernández et al., 2020; Woodruff et al.,
2020; Shuwa et al., 2021).
Some of the lack of reproducibility (leading to the same
methodological considerations) that we emphasized in the
previous paragraph may be also encountered in those studies
dissecting alterations of transitional and naïve B cells in COVID-
19 patients. In addition, a shared agreement about the terms
by which expressing the immunophenotypic features of the
described subset would be extremely beneficial to ensure the
comparability of data (Table 6).
Memory B Cells
Dysregulation of B cell production, survival and turnover in
older subjects affects the ability to respond to new antigens
(thus influencing response to vaccination) and may cause the
accumulation of class switched memory cells (IgD-CD27+),
although the eventuality of such an effect is still a matter of
debate (Ventura et al., 2017; Aiello et al., 2019; Crooke et al.,
2019; Hazeldine and Lord, 2020). Also, age-associated B cells
(ABCs), defined as CD11b+CD11c+CD21low/-T-bet+, increase
with age, and accounts for a reduction in the generation of new B
cells, the release of pro-inflammatory cytokines and autoantibody
production in autoimmune diseases (Rubtsova et al., 2015; Hagen
and Derudder, 2020; Pietrobon et al., 2020; Sachinidis et al., 2020;
Kim C.W. et al., 2021).
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TABLE 6 | Observed fluctuation in naïve and transitional B cells in adult COVID-19 patients.
B cell subset Observation Analyzed patients Compared group(s) References
CD27-IgD+ naïve No change (%) Severeγ Moderateε Shuwa et al., 2021
No change (%) Severeγ Mildδ Shuwa et al., 2021
No change (%) Severeγ HD Shuwa et al., 2021
No change (%) Moderateε Mildδ Shuwa et al., 2021
No change (%) Moderateε HD Shuwa et al., 2021
No change (%) Mildδ HD Shuwa et al., 2021
No change (%) Cases Recovered Mathew et al., 2020
No change (%) Cases HD Mathew et al., 2020
No change (%) Recovered HD Mathew et al., 2020
Increase (%) Severeκ Prepandemic controls Acosta-Ampudia et al., 2021
IgD+CD38–/+ naïve No change (%) Severeη Criticalι Sosa-Hernández et al., 2020
No change (%) Severeη Mild/moderateθ Sosa-Hernández et al., 2020
No change (%) Severeη HD Sosa-Hernández et al., 2020
No change (%) Criticalι Mild/moderateθ Sosa-Hernández et al., 2020
No change (%) Criticalι HD Sosa-Hernández et al., 2020
No change (%) Mild/moderateθ HD Sosa-Hernández et al., 2020
CD21+CD27– naïve No change (%) Recovered HD Long et al., 2021
Naïve Increase (%) Mild/ HD Huang et al., 2021
Increase (%) Moderate/ HD Huang et al., 2021
Increase (%) Cured/ HD Huang et al., 2021
CD24hiCD38hi transitional Reduction (%) Severeγ HD Shuwa et al., 2021
Reduction (%) Severeγ Convalescent Shuwa et al., 2021
CD24+CD38hi transitional No change (%) Severeη HD Sosa-Hernández et al., 2020
Reduction (%) Severeη Mild/moderateθ Sosa-Hernández et al., 2020
Reduction (%) Criticalι Mild/moderateθ Sosa-Hernández et al., 2020
Increase (%) Mild/moderateθ HD Sosa-Hernández et al., 2020
CD27-CD38int CD24+ transitional Reduction (%) ICU Outpatients Woodruff et al., 2020
B cell subset, peripheral blood B cell subset analyzed in the reported studies; (%), as frequency values; (#), as absolute number; Cases, COVID-19 patients (irrespective
of severity); ICU, intensive care unit patients; Recovered, non-hospitalized subjects who had recovered from SARS-CoV-2 infection; HD, healthy donors; Outpatients,
outpatients with milder disease.
γPatients with > 10 L or 60% supplemental oxygen, managed in ICU.
δPatients with < 3L or 28% supplemental oxygen.
εPatients with < 10L or <60% supplemental oxygen, requiring non-invasive ventilation (NIV) or continuous positive airway pressure (CPAP).
ζPatients with clinical signs of pneumonia with one of the following: respiratory rate > 30 breaths/min, severe respiratory distress, or SpO2 < 90% on room air.
ηPatients experiencing the following: respiratory failure, respiratory rate > 30 bpm, oxygen saturation < 92% at rest, arterial partial pressure of oxygen (PaO2)/fraction of
inspired oxygen (FiO2) (PaO2/FiO2) ratio < 300 mmHg.
θFever, signs of airway disease, with or without a tomographic image indicating pneumonia.
ιAny of the following: requirement for mechanical ventilation, shock, or concomitant organ failure.
κRespiratory distress, i.e., ≥30 breaths/min. in resting state, oxygen saturation of 90% or less on room air; or arterial partial pressure of oxygen (PaO2)/fraction of inspired
oxygen (FiO2) of 300 or less.
/No stratification criteria provided.
As regards B cell homeostasis in COVID19+ patients, to the
best of our knowledge only one age focused study explored
the effect of immunosenescence on memory B cell dynamics,
demonstrating that percentage of CD21+CD27+ memory B
cells exhibited a direct correlation with patients age (Kuri-
Cervantes et al., 2020). Data from both COVID-19 patients
(Lenti et al., 2020; Ogega et al., 2021; Shuwa et al., 2021) and
recovered COVID-19 subjects (Long et al., 2021) showed no
effects in terms of memory B cell accumulation, resembling those
reports documenting a similar scenario during aging (Crooke
et al., 2019). These findings were not confirmed by all the
available studies, mainly because of differences in the patient
stratification criteria, insufficient sample size and inconsistency
in the evaluated immunophenotypic features that were used to
detect the desired subset (Table 7; Carsetti et al., 2020; Lenti
et al., 2020; Mathew et al., 2020; Sosa-Hernández et al., 2020;
Acosta-Ampudia et al., 2021; Shuwa et al., 2021).
Only depletion of peripheral IgM+ memory B cells seems to be
a hallmark of SARS-CoV-2 infection (Carsetti et al., 2020; Lenti
et al., 2020). Intriguingly, the percentage of IgM+ and switched
memory B cells showed an inverse correlation with symptoms
duration in convalescent patients, with no age or gender related
influence (Newell et al., 2021).
As expected in immunocompetent subjects, seroconversion
is positively associated with frequency of switched memory
B cells, IgM+ memory B cells, CD19+CD27hiIgM-IgD+
c-delta switched memory B cells, and CD19+ CD11c+Tbet+
ABCs, whose percentages are higher in patients with a high
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seroconversion index vs. patients with a low seroconversion
index (Galbraith et al., 2021).
Late memory CD27-IgD- Double negative (DN) B cells
are exhausted memory cells that actively contribute to the
inflammatory status associated with aging by secreting
TNF-α and IL-6 (Bulati et al., 2014; Crooke et al., 2019;
Fraussen et al., 2019; Ma et al., 2019; Hagen and Derudder, 2020;
Pietrobon et al., 2020).
DN B lymphocytes reached a statistically significant expansion
in both COVID-19 patients and convalescent subjects vs. controls
(Table 7; Mathew et al., 2020; Shuwa et al., 2021). However, at
an individual patient level, DN B cell fraction tends to decrease
TABLE 7 | Observed fluctuation in B cells in adult COVID-19 patients.
B cells Observation Analyzed patients Compared group(s) References
CD21+CD27+ memory Reduction (%) Severeρ HD Kuri-Cervantes et al., 2020
CD27+IgD+ unswitched memory No change (%) Severeγ Moderateε Shuwa et al., 2021
No change (%) Severeγ Mildδ Shuwa et al., 2021
No change (%) Severeγ HD Shuwa et al., 2021
No change (%) Moderateε Mildδ Shuwa et al., 2021
No change (%) Moderateε HD Shuwa et al., 2021
No change (%) Mildδ HD Shuwa et al., 2021
Increase (%) Severeκ Prepandemic controls Acosta-Ampudia et al., 2021
Reduction (%) Severeη HD Sosa-Hernández et al., 2020
Reduction (%) Criticalι HD Sosa-Hernández et al., 2020
Reduction (%) Cases Recovered Mathew et al., 2020
Reduction (%) Cases HD Mathew et al., 2020
IgD+IgM+ unswitched memory No change (%) Severe Mild Ogega et al., 2021
No change (%) Severe HD Ogega et al., 2021
No change (%) Mild HD Ogega et al., 2021
CD27+IgD- switched memory No change (%) Severeγ Moderateε Shuwa et al., 2021
No change (%) Severeγ Mild δ Shuwa et al., 2021
No change (%) Severeγ HD Shuwa et al., 2021
No change (%) Moderateε Mild δ Shuwa et al., 2021
No change (%) Moderateε HD Shuwa et al., 2021
No change (%) Mildδ HD Shuwa et al., 2021
Reduction (%) Severeη HD Sosa-Hernández et al., 2020
Reduction (%) Cases Recovered Mathew et al., 2020
Reduction (%) Cases HD Mathew et al., 2020
CD27-IgM- switched memory Reduction (%) Severeζ Mildπ Carsetti et al., 2020;
CD38+/–IgM–IgD– switched memory No change (%) Severeλ Mildµ Ogega et al., 2021
No change (%) Severeλ HD Ogega et al., 2021
No change (%) Mildµ HD Ogega et al., 2021
No change (#) Cases HD Lenti et al., 2020
No change (#) Cases Hypofunctionν Lenti et al., 2020
No change (#) Cases Splenectomyξ Lenti et al., 2020
CD27+IgD-IgM-CD38+ switched memory Increase (%) Severeκ Prepandemic controls Acosta-Ampudia et al., 2021
IgM+ memory Reduction (%) Severeζ Asymptomatic Carsetti et al., 2020
Reduction (%) Severeζ Mildπ Carsetti et al., 2020
Reduction (%) Cases HD Lenti et al., 2020
IgM-IgG- memory Increase (%) Severeζ Asymptomatic Carsetti et al., 2020
Increase (%) Severeζ Mildπ Carsetti et al., 2020
CD27-IgD- double negative memory Increase (%) Severeγ HD Shuwa et al., 2021;
Increase (%) Convalescent HD Shuwa et al., 2021;
Increase (%) Cases Recovered Mathew et al., 2020
Increase (%) Cases HD Mathew et al., 2020
CD38–/+CD24–CD21+CD11c– DN1 Reduction (%) Severeη Mild/moderateθ Sosa-Hernández et al., 2020
Reduction (%) Critical ι Mild/moderate θ Sosa-Hernández et al., 2020
CD38–CD24-CD21–CD11c+ DN2 Increase (%) Severeη Mild/moderateθ Sosa-Hernández et al., 2020
Increase (%) Severeη Criticalι Sosa-Hernández et al., 2020
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TABLE 7 | Continued
B cells Observation Analyzed patients Compared group(s) References
CD38–/+CD24–CD21–CD11c– DN3 Increase (%) Severeη HD Sosa-Hernández et al., 2020
Increase (%) Criticalι Mild/moderateθ Sosa-Hernández et al., 2020
Increase (%) Criticalι HD Sosa-Hernández et al., 2020
B cell subset, peripheral blood B cell subset analyzed in the reported studies; BAL, bronchoalveolar lavage; (%), as frequency values; (#), as absolute number; Cases,
COVID-19 patients (irrespective of severity); ICU, intensive care unit patients; Recovered, non-hospitalized subjects who had recovered from SARS-CoV-2 infection; HD,
healthy donors; Outpatients, outpatients with milder disease; ARDS, acute respiratory distress syndrome; NCU, normal care unit patients; NCU (non-COVID-19), normal
care unit patients treated for other reasons than COVID-19; ICU (non-COVID-19), intensive care unit patients treated for other reasons than COVID-19; Asymptomatic,
patients who tested positive but had no symptoms.
ρ included subjects were in the following condition(s): high flow nasal cannula–noninvasive, ventilator (non-ARDS), mild to severe ARDS, and ECMO.
γPatients with > 10L or 60% supplemental oxygen, managed in ICU.
δPatients with < 3L or 28% supplemental oxygen.
εPatients with < 10L or < 60% supplemental oxygen, requiring non-invasive ventilation (NIV) or continuous positive airway pressure (CPAP).
ζPatients with clinical signs of pneumonia with one of the following: respiratory rate > 30 breaths/min, severe respiratory distress, or SpO2 < 90% on room air.
ηPatients experiencing the following: respiratory failure, respiratory rate > 30 bpm, oxygen saturation < 92% at rest, arterial partial pressure of oxygen (PaO2)/fraction of
inspired oxygen (FiO2) (PaO2/FiO2) ratio < 300 mmHg.
θFever, signs of airway disease, with or without a tomographic image indicating pneumonia.
ιAny of the following: requirement for mechanical ventilation, shock, or concomitant organ failure.
κRespiratory distress, i.e., ≥ 30 breaths/min. in resting state, oxygen saturation of 90% or less on room air; or arterial partial pressure of oxygen (PaO2)/fraction of inspired




ξPatients who underwent splenectomy for trauma.
πPatients requiring no hospitalization and experiencing symptoms like with fever, myalgia, and fatigue without obvious chest high resolution computed tomography findings
for COVID-19.
from acute disease to convalescent status (Newell et al., 2021;
Shuwa et al., 2021). A keen characterization of DN B cell subsets,
revealed that the increase of DN B cells in severe and critical
patients may be attributable to an augmented CD38–CD24–
CD21–CD11c+ DN2 and CD38–/+CD24–CD21–CD11c– DN3
fraction (Table 7; Sosa-Hernández et al., 2020).
As regards SARS-CoV-2 specific memory, widening evidences
demonstrated that generation of SARS-CoV-2 memory B cells
initiates early after infection/symptoms onset and is durable
(Hartley et al., 2020; Abayasingam et al., 2021; Byazrova et al.,
2021; Carsetti et al., 2021; Dan et al., 2021; Gaebler et al., 2021;
Long et al., 2021; Ogega et al., 2021; Sakharkar et al., 2021; Sherina
et al., 2021; Sokal et al., 2021; Tong et al., 2021). It remains to be
deepened if sex may play a role in influencing the time of onset of
B cell memory in COVID-19 subjects.
Plasma Blasts and Antibody Secreting
Cells
Aging hampers the proper differentiation of B cells into plasma
cells (Ventura et al., 2017; Crooke et al., 2019; Hazeldine and
Lord, 2020). This phenomenon seems to be avoided during
SARS-CoV-2 infection, since the plasmblast fraction of B cells
was reported as augmented in all patients whereas levels tend to
be restored in convalescent and recovered patients (Mathew et al.,
2020; Sosa-Hernández et al., 2020; Long et al., 2021; Shuwa et al.,
2021; Wildner et al., 2021; Table 8). This piece of data reflects an
infection related reactive expansion, given that the percentage of
plasma cells positively correlates with the fraction of IgG+ and
IgA+ positive B cells (Shuwa et al., 2021). The increase in plasma
cells showed a direct correlation with an oligoclonal expansion of
antibody clones (Kuri-Cervantes et al., 2020). Reported evidences
for COVID-19 seem to recall the contraction of the B cell
repertoire which was demonstrated in older people, although the
involvement of the same molecular mechanisms remains to be
elucidated (Aiello et al., 2019; Crooke et al., 2019; Ma et al., 2019;
Lian et al., 2020). Obviously, plasma cells exhibited a significant
association with seroconversion, with frequencies being higher in
patients with high seroconversion indices vs. those with low ones
(Galbraith et al., 2021).
Similar results were replicated at the lung level. In fact, the
total number and proportion of BAL plasma cells was increased in
COVID-19 patients (according with disease severity) vs. healthy
controls (Kim C.W. et al., 2021).
B Cell Trafficking Phenotype
B cell trafficking phenotype exhibits profound modification
during aging (Bulati et al., 2014).
During acute COVID-19, B cells showed a reduced expression
of CXCR3, CXCR5 and integrin β7 according to disease severity,
with CXCR3 and CXCR5 level normalization in convalescent
subjects (Shuwa et al., 2021).
With a detailed characterization of B cell subsets, it was
documented that CXCR5 expression was reduced on naïve,
plasmablasts, and memory B cells, including DN memory B
cells (Kuri-Cervantes et al., 2020; Mathew et al., 2020). This
is a very intriguing piece of data, since CXCR5 did not show
any statistically significant difference in its expression on B
lymphocyte subsets comparing young and old subjects (Bulati
et al., 2014), thus it is not expected to be differentially modulated
in COVID-19 as a consequence of aging.
BAL B lymphocytes from patients with mild disease express
CCR6 and CXCR3, whereas BAL B cells from patients with
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TABLE 8 | Observed fluctuation in ASCs and plasmablasts in adult COVID-19 patients.
ASCs and plasmablasts Observation Analyzed patients Compared group(s) References
CD19+/–IgM–IgD–CD38+/+ ASCs No change (%) Severeλ Mildµ Ogega et al., 2021
No change (%) Severeλ HD Ogega et al., 2021
No change (%) Mildµ HD Ogega et al., 2021
CD19+CD21–CD27+CD38+/high ASCs No change Recoveredς HD Long et al., 2021
CD27hiCD38hi plasmblasts Increase (%) Severeγ Convalescent Shuwa et al., 2021
Increase (%) Severeγ HD Shuwa et al., 2021
Increase (%) Moderateε Convalescent Shuwa et al., 2021
Increase (%) Moderateε HD Shuwa et al., 2021
Increase (%) Mildδ HD Shuwa et al., 2021
Increase (%) Convalescent HD Shuwa et al., 2021
CD27+CD38+ plasmablasts Increase (%) Cases Recoveredρ Mathew et al., 2020
Increase (%) Cases HD Mathew et al., 2020
Increase (%) Cases HD Wildner et al., 2021;
Increase (%) ICU Outpatients Woodruff et al., 2020
Increase (%) ICU HD Woodruff et al., 2020
CD27+ CD38hi ASC/plasmablasts Increase (%) Severeη HD Sosa-Hernández et al., 2020
Increase (%) Criticalι HD Sosa-Hernández et al., 2020
Increase (%) Mild/moderateθ HD Sosa-Hernández et al., 2020
CD38+CD24– plasmablasts Increase (%) Severeζ Asymptomatic Carsetti et al., 2020
Increase (%) Severeζ Mildπ Carsetti et al., 2020
Increase (%) Severeζ Contactsσ Carsetti et al., 2020
ASCs, antibody secreting cells; (%), as frequency values; Cases, COVID-19 patients (irrespective of severity); ICU, intensive care unit patients; HD, healthy donors;
Outpatients, outpatients with milder disease; Asymptomatic, patients who tested positive but had no symptoms.
γPatients with > 10 L or 60% supplemental oxygen, managed in ICU.
δPatients with < 3 L or 28% supplemental oxygen.
εPatients with < 10 L or <60% supplemental oxygen, requiring non-invasive ventilation (NIV) or continuous positive airway pressure (CPAP).
ζPatients with clinical signs of pneumonia with one of the following: respiratory rate > 30 breaths/min, severe respiratory distress, or SpO2 < 90% on room air.
ηPatients experiencing the following: respiratory failure, respiratory rate > 30 bpm, oxygen saturation < 92% at rest, arterial partial pressure of oxygen (PaO2)/fraction of
inspired oxygen (FiO2) (PaO2/FiO2) ratio < 300 mmHg.
θFever, signs of airway disease, with or without a tomographic image indicating pneumonia.
ιAny of the following: requirement for mechanical ventilation, shock, or concomitant organ failure.
κRespiratory distress, i.e., ≥30 breaths/min. in resting state, oxygen saturation of 90% or less on room air; or arterial partial pressure of oxygen (PaO2)/fraction of inspired




ξPatients who underwent splenectomy for trauma.
πPatients requiring no hospitalization and experiencing symptoms like with fever, myalgia, and fatigue without obvious chest high resolution computed tomography
findings for COVID-19.
ρNon-hospitalized subjects who had recovered from SARS-CoV-2 infection.
ςAdults with a prior positive COVID-19 PCR test who met the definition of recovery based on the guideline from the Chinese Center for Disease Control and Prevention.
σContacts of SARS-CoV-2 confirmed cases who were negative by qPCR.
severe disease express more CXCR4 vs patients with mild
disease and healthy subjects (Kim C.W. et al., 2021). Given
that both CCR6 and CXCR4 are involved in B cell circulation
to lymph nodes, whereas CXCR3 (whose gene is located on
X chromosome)1 rules B cell attraction to inflammation sites
(Kunkel and Butcher, 2003), it would be worth deepening if BAL
B cells from COVID-19 exhibit different B cell trafficking features
according to both severity and gender. Also, in severe patients,
BAL plasma cells had an increased expression of CCR2 and
CCR10 (Kim C.W. et al., 2021). CCR2 is normally expressed on
normal plasma cells, is renowned for mediating homing aberrant
1https://www.genecards.org/cgi-bin/carddisp.pl?gene=CXCR3&keywords=cxcr3
(accessed July 22, 2021).
plasma cells in multiple myeloma and is downregulated during
B cell maturation, while CCR10 is highly expressed by IgA
producing plasma cells (Vande Broek et al., 2003; Flaishon et al.,
2004; Shirakawa et al., 2008; Hu et al., 2011). Also, in terminally
differentiating B cells CCR10 expression may be induced by 1,25-
Dihydroxyvitamin D3, a known modulator of B cell homeostasis
that showed a correlation with COVID-19 severity (Martens
et al., 2020; Notz et al., 2021).
Functional Considerations About B Cells
As previously mentioned, inflammageing -defined as the balance
between inflammatory and anti-inflammatory mechanisms
pending toward inflammation- is a typical hallmark of an aging
immune system (Ventura et al., 2017; Hazeldine and Lord, 2020).
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COVID-19 offers the chance to improve the knowledge about
the deregulation of molecular mechanisms ruling the production
of inflammatory mediators. In fact, cytokine storm, characterized
by increased circulating cytokine levels, with potential life-
threatening acute systemic inflammation and secondary organ
dysfunction, is a prominent feature of SARS-CoV-2 infection
especially in severe cases (see section “Cytokine storm in COVID-
19 disease”).
As expected, after TLR9 agonist CpGB stimulation the
percentage of IL-6+ B cells increased in acute COVID-19 patients
vs. healthy controls and convalescent patients irrespective of
possible chest X-ray abnormality (Shuwa et al., 2021). On the
contrary, the percentage of IL-10+ B cells was significantly lower
in patients with persistent lung pathology vs. healthy controls
and normal chest X-ray subjects (Shuwa et al., 2021). However,
analyzed at an individual patient level, the frequency of IL-
10+ B cells increased from acute phase to convalescent status
(Shuwa et al., 2021).
Transcriptomic analysis revealed that B cell immune answers
are predominant in BAL fluid (Cavalli et al., 2020), and that BAL
B cells from severe COVID-19 patients were highly activated by
TNF-α signaling (Kim C.W. et al., 2021). B-cell activating factor
(BAFF) receptor and transmembrane activator and calcium
modulator and cyclophilin ligand interactor were expressed by
all patients, but in severe patients there was an upregulation of
apoptosis related gene transcription, probably mediated by BAFF
signaling (Kim C.W. et al., 2021).
Study of peripheral B lymphocytes revealed a pattern of
activation/exhaustion, characterized by increased frequency of
CD69 and CD95 in hospitalized subjects vs. healthy controls
and convalescent patients, and by an increase in PD1 frequency
in non-hospitalized (convalescent) individuals vs. both healthy
controls and COVID-19 hospitalized patients (Files et al., 2021).
This may mirror the establishment of efficient mechanisms
modulating strength and durability of B cell responses in
convalescent subjects, given that both CD69 and CD95 are
markers of lymphocyte activation (Catlett and Bishop, 1999;
Vazquez et al., 2009), whereas PD1 is an immune modulator
(Wang et al., 2019). Also, CD95 expression is increased on
CD27+ B cells from older individuals vs. younger donors (Chong
et al., 2005), and might be involved in age related differences in
the regulation of anti-SARS-CoV-2 immune responses.
MESENCHYMAL STEM CELL
TRANSPLANTATION IN COVID-19
PATIENTS: RATIONALE AND RESULTS
Mesenchymal stem cells, also known as mesenchymal stromal
cells (MSCs) (Viswanathan et al., 2019), are heterogeneously
multipotent stem cells that can be isolated from a variety
of sources, including umbilical cord, human tissues like
bone marrow and adipose tissue (using the stromal vascular
fraction – SVF), and menstrual blood (Blaber et al., 2012;
Kallmeyer and Pepper, 2015; Elgaz et al., 2019; Copcu, 2020;
Gentile and Sterodimas, 2020a,b; Jeyaraman et al., 2020;
Juárez-Navarro et al., 2020; Lin et al., 2020; Barros et al., 2021;
Gentile, 2021; Mazini et al., 2021; Xu et al., 2021).
Mesenchymal stem cells are universally renowned for their
unique immunomodulatory properties; once led into circulation,
they are able to reach inflammation sites (Kallmeyer and Pepper,
2015), where they exert an inhibitory function on neutrophils,
monocytes, dendritic cells, NK, B and T lymphocytes (Elgaz
et al., 2019; Juárez-Navarro et al., 2020; Kim H. et al., 2020;
Moradinasab et al., 2021). MSC ruled immunomodulation
is performed by direct cell–cell interaction (through the
expression of molecules like B7H1, PD-L1, and PD-L2) (Elgaz
et al., 2019; Lin et al., 2020) as well as by a paracrine
action, mediated by vehiculation of anti-inflammatory mediators
through extracellular vesicles (Schulman et al., 2018; Martin-
Rufino et al., 2019; Gowen et al., 2020; Juárez-Navarro et al.,
2020; Kim H. et al., 2020; Lin et al., 2020; O’Driscoll, 2020;
Wang J. et al., 2020; Gentile, 2021; Raghav et al., 2021; Su
et al., 2021) and by cytokine (IL-10, transforming growth factor-
β, TNF-stimulated gene 6 protein, IFN-γ) and soluble factor
indoleamine-pyrrole 2,3-dioxygenase, prostaglandinE2, nitric
oxide) secretion (Schulman et al., 2018; Elgaz et al., 2019; Martin-
Rufino et al., 2019; Juárez-Navarro et al., 2020; Lin et al., 2020;
Shetty, 2020; Gentile, 2021; Raghav et al., 2021). MSC polarization
toward an anti-inflammatory phenotype is exacerbated by TLR
stimulation elicited by pathogen components, like viral RNA
(Waterman et al., 2010). Also, MSCs retain a differentiation
potential making them ideal contributors to tissue repair (Blaber
et al., 2012; Kallmeyer and Pepper, 2015; Elgaz et al., 2019;
Copcu, 2020; Jeyaraman et al., 2020; Juárez-Navarro et al., 2020;
Rogers et al., 2020).
As suggested by successful MSC use in a number of
pathological scenarios involving uncontrolled immune activation
with consequent tissue damage, like for example H9N2 induced
acute lung injury, ARDS, autoimmune diseases and graft-versus-
host disease (Waterman et al., 2010; Elgaz et al., 2019; Coelho
et al., 2020; Yen et al., 2020; Barros et al., 2021; Musial and
Gorska-Ponikowska, 2021; Su et al., 2021), the undeniable
immunomodulatory and inflammation relieving properties of
MSCs make them putative candidates as rejuvenating factors
for the older immune system, on the basis of the documented
ability to reduce pro-inflammatory mediators and to promote the
expansion of regulatory lymphocyte subsets (Yeo et al., 2021).
Also, MSC transplantation can contribute to the amelioration of
aging frailty (Schulman et al., 2018; Florea et al., 2019; Sun et al.,
2019), but MSC may exhibit age related deteriorating functions
linked to inflammageing, especially in terms of alterations in
number and characteristics of extracellular vesicles, DAMP
production, excessive IL-6 release, loss of MSC ability to shift
monocyte polarization toward M2, and triggering of ineffective
hemopoiesis (Tsuruhara et al., 2017; Lee and Yu, 2020). Potency
also seems to be affected by aging in bone marrow derived
MSCs (BM-MSCs), but not in MSC obtained from adipose tissue
(Rogers et al., 2020).
Assuming also that MSCs are negative for ACE2 and
TMPRSS2 SARS-CoV-2 receptor complex (Leng et al., 2020;
Moradinasab et al., 2021), MSC transplantation or infusion of
MSC derived extracellular vesicles in the context of a deregulated
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FIGURE 1 | A schematic view of how immunopathology and immunosenescence could contribute to severe COVID-19 in older people. PAMPs, pathogen
associated molecular patterns; ROS, reactive oxygen species. See text for other acronyms.
immune response, cytokine storm and lung injury elicited during
COVID-19 (especially in older people) appeared as a promising
strategy (Gentile and Sterodimas, 2020a,b; Gorman et al., 2020;
Monguió-Tortajada et al., 2020; Qin and Zhao, 2020; Rogers et al.,
2020; Tsuchiya et al., 2020; Gentile, 2021; Raza et al., 2021).
Following the first paper by Leng et al. (2020) (see below),
a number of data extrapolated from ongoing and concluded
clinical studies on COVID-19 patients using both BM-MSCs
and umbilical cord MSCs (UC-MSCs), together with reports
employing MSCs from other sources or MSC vesicles, with
positive results have been published so far (Al-Khawaga and
Abdelalim, 2020; Barkama et al., 2020; Gentile et al., 2020;
Golchin et al., 2020; Gorman et al., 2020; Liang et al., 2020; Lin
et al., 2020; Meng F. et al., 2020; Sánchez-Guijo et al., 2020;
Sengupta et al., 2020; Shu et al., 2020; Gentile, 2021; Jamshidi
et al., 2021; Kouroupis et al., 2021; Moradinasab et al., 2021;
Payares-Herrera et al., 2021; Sharma and Zhao, 2021).
In that paper, Leng et al. (2020) showed that MSCs cured
or significantly improved the functional outcomes of seven
patients without observed adverse effects. After treatment, the
peripheral lymphocytes were increased, the C-reactive protein
as well as TNF-α decreased, while IL-10 increased, and the
overactivated cytokine-secreting immune cells CXCR3+CD4+ T
cells, CXCR3+CD8+ T cells, and CXCR3+ NK cells disappeared
in 3–6 days. In addition, a group of CD14+CD11c+CD11bmid
regulatory DC cell population dramatically increased. Therefore,
the intravenous transplantation of MSCs was safe and effective
for treatment in patients with COVID-19 pneumonia, especially
for patients in critically severe condition.
It was then demonstrated that both BM- and UC-MSCs
showed to be able to improve COVID-19 survival rates (Shu
et al., 2020; Häberle et al., 2021; Lanzoni et al., 2021; Moradinasab
et al., 2021), symptoms (Liang et al., 2020; Meng F. et al.,
2020; Shu et al., 2020; Tang et al., 2020; Zengin et al., 2020;
Hashemian et al., 2021; Moradinasab et al., 2021), pulmonary
functions (Liang et al., 2020; Meng F. et al., 2020; Shu et al., 2020;
Zengin et al., 2020; Häberle et al., 2021; Moradinasab et al.,
2021), inflammatory marker levels (CRP, TNF-α, neutrophil
extracellular traps, IL-1RA, IL-5, IL-6, IL-18, IL-27, IL-17E/IL-
25, IL-17F, CXCL-1, neutrophil-to-lymphocyte ratio, D-dimer)
(Guo Z. et al., 2020; Liang et al., 2020; Tang et al., 2020;
Zengin et al., 2020; Zhang Y. et al., 2020; Hashemian et al., 2021;
Lanzoni et al., 2021; Moradinasab et al., 2021) and lymphopenia
(Guo Z. et al., 2020; Liang et al., 2020; Zhu Y. et al., 2020) after
few days of treatment. Placenta derived MSCs (Barkama et al.,
2020), adipose derived MSCs (Sánchez-Guijo et al., 2020) and
menstrual blood derived MSCs (Xu et al., 2021) showed to have
similar effects.
In the context of the possible therapeutic use of MSCs to
promote lung regeneration in COVID19, adipose and bone
marrow derived MSCs are able to contribute to lung regeneration
in animal models, by differentiation into type 2 alveolar epithelial
cells and their immunomodulatory potential; in the case of
adipose derived MSC, the success of both mechanisms is
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facilitated by their large availability (Copcu, 2020; Behnke et al.,
2020; Gentile and Sterodimas, 2020a,b; Rogers et al., 2020). The
same regenerative properties are shown by SVF, whose cellular
components secrete pro-angiogenetic and immune-modulating
mediators (Gentile and Sterodimas, 2020a,b; Gentile, 2021).
As regards the preference for autologous rather than allogenic
alternatives, the choice is influenced by limited time availability
as well as intrinsic dependence of MSC properties on the
age of the donor; in fact, given that also MSC experience
senescence (Lee and Yu, 2020), the choice of allogenic MSCs
or more senescence resistant adipose derived MSC may
be recommendable in older patients (Rogers et al., 2020;
Moradinasab et al., 2021).
Molecular mechanisms triggered by MSC infusion and by
exosome derived MSCs in COVID-19 patients are currently
under investigation. As regards immune cell homeostasis,
overactivated cytokine-secreting immune cells CXCR3+CD4+ T
cells, CXCR3+CD8+ T cells, and CXCR3+ NK cells disappeared
soon after the MSC transplantation (Leng et al., 2020), with a
general increase in both percentage and count of B lymphocytes,
NK, CD3+, CD4+ and CD8+ cells (Liang et al., 2020; Sengupta
et al., 2020; Tang et al., 2020; Zhang Y. et al., 2020; Zhu Y.
et al., 2020) up to the decrease of neutrophil-to-lymphocyte
ratio (Liang et al., 2020). This is nice food for thought, since
MSC immunomodulation activity is exerted through inhibition
of B, CD4+ and CD8+ T cell proliferation (Budoni et al.,
2013; Joel et al., 2019; Moradinasab et al., 2021). Instead,
MSC action on neutrophils is mainly functional rather than
“numerical” (Li and Hua, 2017; Joel et al., 2019; Lin et al., 2020;
Moradinasab et al., 2021), but the available data demonstrate
that in more severe COVID-19 cases and in deceased patients
neutrophils are also more abundant other that involved in
cytokine storm establishment (see sections “Introduction” and
“Neutrophils”). It remains to be demonstrated that MSC elicited
an increase in COVID-19 T and B cell numbers may be
related to an increase in the proportion of Tregs or Bregs,
as observed in other contexts (Joel et al., 2019; Liu J. et al.,
2020; Moradinasab et al., 2021) or if the apoptotic rate in
neutrophils may be increased specifically in MSC treated patients.
MSCs hamper B cell differentiation into plasma cells (Tsuruhara
et al., 2017; Moradinasab et al., 2021); the same effect on
COVID-19 patients and eventual consequences on anti-SARS-
CoV-2 antibody production deserve further investigation. In
addition, MSCs alter B cell trafficking phenotype, including
downregulation of CXCR4 and CXCR5 (Joel et al., 2019), that
are differentially regulated in COVID-19 (see section “B Cell
Trafficking Phenotype section”). Molecular changes elicited by
MSC influencing recirculation of B cells to lungs in the case of
SARS-CoV-2 infection are still unexplored. Finally, given DN
B cell increase in both immunosenescence and COVID-19 (see
section “Memory B cells”), the potential rejuvenating effect of
MSC on the exhausted subset, like DN B cells, might represent
a putative mechanism of action contributing to the amelioration
of these inflammatory conditions.
Similarly, (as mentioned above) CD14+CD11c+CD11bmid
regulatory DC cell population increased after MSC
transplantation, (Leng et al., 2020). The origin of
CD14+CD11c+CD11bmid regulatory DC cells deserve to
be assessed, because (I) CD11c+ DCs are reported as reduced
in COVID-19 patients and show multiple functional alterations
[see section “Dendritic cells (DCs)”] (II) the exploration of
such an ontological pattern would put some more light on
monocyte dynamics. CD11c is highly expressed by conventional
DC2, powerful stimulators of naïve T cells (Rhodes et al., 2019)
reduced in COVID-19 [see section “Dendritic cells (DCs)”]
and by monocyte derived DCs (Delirezh et al., 2011; Boyette
et al., 2017; Rhodes et al., 2019; Chometon et al., 2020). Despite
this detail, no functional defects in conventional DC2 or
monocyte derived DCs generation were studied in SARS-CoV-2
infected individuals so far. Data for better IL-1β, IL-6, and
TNF-α producer classical macrophages (CD16-) are instead
more commonly settled on detecting no variation in their
frequency (see section “Monocytes and macrophages”). Since
all monocytes are able to differentiate into macrophages, but
(I) classical monocytes have a superior ability to differentiate
into monocyte derived DCs (expressing CD11c) and (II)
the relationship between conventional DC2 and monocytes
is controversial (Delirezh et al., 2011; Boyette et al., 2017;
Rhodes et al., 2019; Chometon et al., 2020), it would be worth
discovering what molecular pathways are activated in classical
monocytes by interacting with MSCs that may influence their
immunophenotypic and functional faith.
Also, DCs exhibit a number of functional alterations in
COVID-19, including reduced expression of CD86 and HLA-
DR, whose upregulation is specifically hampered by MSCs during
DC maturation (Joel et al., 2019). It remains to be assessed if
this effect of MSCs on DCs is summed to that elicited by the
microenvironment in SARS-CoV-2 infected tissue.
Together, these results underscore the role of MSCs in
improving COVID-19 patient outcomes via maintenance of
immune homeostasis, i.e., improving immunosenescence and
relieving immunopathology.
CONCLUSION
Summarizing clinical findings discussed in the present paper,
it is clear that the synergistic effects of immunosenescence and
inflammageing (i.e., immunopathology) in older individuals have
an important impact on their immune responses to SARS-
CoV-2 infection (Figure 1) and should be taken into account
whenever looking for factors influencing mortality rates in
COVID-19 (Salimi and Hamlyn, 2020; Bajaj et al., 2021; Chen
Y. et al., 2021). Changes in innate immune responses and
the failure to trigger an effective acquired immune response
(i.e., immunosenescence), in combination with a higher pro-
inflammatory status (i.e., immunopathology) should explain why
older people do not appropriately control viral replication and
the potential clinical consequences triggered by a cytokine storm,
also reducing the chances of proper recovery after infection
resolution (Salimi and Hamlyn, 2020; Bajaj et al., 2021; Chen
Y. et al., 2021). This awareness is critical to the implementation
of any strategy aimed at improving protective immunity and
vaccine efficacy against SARS-CoV-2 in the older population
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(Bajaj et al., 2021). Regarding the gender differences in SARS-
CoV-2 infection outcome reported in the present review,
most studies are observational only and do not take into
account that males and females may have several pre-existing
conditions affecting the chance of successful aging, hence
involving different responses to virus infection (Leng and
Margolick, 2020; Mauvais-Jarvis et al., 2020; Sampathkumar et al.,
2020; Ligotti et al., 2021; Lio et al., 2021). The key roles of
immunosenescence and immunopathology in the outcome of
SARS-CoV-2 infection are further supported by the beneficial
results obtained with MSC infusion that, as previously discussed,
act restoring immune homeostasis and contributing to lung
repair (Gentile and Sterodimas, 2020a,b; Gorman et al., 2020;
Monguió-Tortajada et al., 2020; Qin and Zhao, 2020; Rogers
et al., 2020; Tsuchiya et al., 2020; Gentile, 2021; Raza et al.,
2021). Therefore, the enhancement of the efficacy of the acquired
immune response and the relief of the pro-inflammatory status
should be an important issue both for SARS-CoV-2 infection
resolution as well as for the appropriate generation of immunity
upon vaccination.
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